Alfredo Falcone

Q: What Schools Are Affiliated With Alfredo Falcone

Alfredo Falcone is affiliated with the following schools: University of California, Berkeley, Consorzio ICoN, University of Urbino, Marche Polytechnic University, Cardiff University, Stanford University, Sapienza University of Rome, Monash University

Alfredo Falcone's AcademicInfluence.com Rankings

Alfredo Falcone

Computer Science

#7644

World Rank

#8048

Historical Rank

Computational Linguistics

#1562

World Rank

#1579

Historical Rank

Machine Learning

#2890

World Rank

#2926

Historical Rank

Artificial Intelligence

#3183

World Rank

#3230

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Alfredo Falcone's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Alfredo Falcone Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alfredo Falcone's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016) (2368)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial (2013) (2113)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. (2007) (1091)
Randomized trial of TAS-102 for refractory metastatic colorectal cancer. (2015) (886)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients (2015) (823)
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. (2014) (798)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial (2018) (791)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. (2015) (753)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer (2009) (550)
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. (2010) (439)
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. (2009) (425)
Primary tumor location as a prognostic factor in metastatic colorectal cancer. (2015) (376)
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. (2016) (371)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. (2007) (287)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. (2019) (282)
Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. (2015) (281)
Quantitative evidence for early metastatic seeding in colorectal cancer (2019) (267)
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. (2010) (251)
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. (2008) (241)
Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases (2009) (228)
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial (2019) (227)
Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients (2008) (209)
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. (2017) (208)
A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs (2015) (190)
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. (2014) (181)
Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy (2009) (171)
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study (2004) (166)
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. (2011) (162)
Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer (2006) (160)
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis (2012) (156)
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC (2018) (155)
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. (2002) (149)
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study) (2009) (140)
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. (2015) (139)
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. (2020) (135)
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection (2015) (134)
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. (2008) (134)
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. (2007) (132)
First-line chemotherapy for mCRC—a review and evidence-based algorithm (2015) (131)
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? (2012) (130)
Hypersensitivity reactions related to oxaliplatin (OHP) (2003) (130)
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. (2015) (129)
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. (2008) (128)
Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan (2010) (126)
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer (2015) (124)
Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. (2005) (121)
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. (2004) (113)
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. (2001) (108)
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. (2015) (106)
Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. (2016) (106)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy (2008) (105)
Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. (2010) (98)
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO (2017) (97)
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. (2000) (97)
Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients (2015) (96)
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib (2008) (95)
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. (2012) (92)
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer (2011) (89)
The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. (2013) (89)
Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer (2009) (88)
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). (2013) (88)
Anti-HER agents in gastric cancer: from bench to bedside (2011) (88)
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. (2020) (86)
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. (2016) (85)
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. (2015) (83)
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project (2018) (82)
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. (2018) (81)
FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. (2013) (80)
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA (2016) (78)
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis (2009) (77)
Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. (2012) (76)
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer (2016) (76)
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial (2018) (74)
High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. (2012) (74)
Insulin‐like growth factor 1 expression correlates with clinical outcome in K‐RAS wild type colorectal cancer patients treated with cetuximab and irinotecan (2010) (73)
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer (2011) (72)
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer (2014) (70)
High-Throughput MicroRNA (miRNAs) Arrays Unravel the Prognostic Role of MiR-211 in Pancreatic Cancer (2012) (70)
Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. (2012) (70)
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. (2011) (69)
Current status and perspectives in immunotherapy for metastatic melanoma (2015) (69)
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study (2020) (69)
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients (2011) (69)
A pharmacokinetic‐based test to prevent severe 5‐fluorouracil toxicity (2006) (69)
5-Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies. (1990) (68)
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients (2008) (68)
Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab (2013) (67)
Comment on: ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort' (2016) (67)
Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib (2010) (66)
Correlation Between Cytidine Deaminase Genotype and Gemcitabine Deamination in Blood Samples (2008) (65)
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers (2012) (64)
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected (2018) (64)
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case–control study (2017) (64)
Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients. (2009) (64)
Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. (2001) (62)
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. (2015) (62)
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials (2010) (61)
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. (2016) (60)
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. (2015) (60)
Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. (2007) (60)
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. (2011) (60)
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer (2017) (58)
VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population (2009) (57)
Baseline elevated leukocyte count in peripheral blood is associated with poor survival in patients with advanced non-small cell lung cancer: a prognostic model (2008) (57)
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. (2011) (56)
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients (2019) (55)
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. (2019) (55)
5-Fluorouracil Pharmacokinetics Predicts Disease-free Survival in Patients Administered Adjuvant Chemotherapy for Colorectal Cancer (2008) (55)
Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin. (2006) (54)
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. (2014) (53)
Interprofessional spiritual care in oncology: a literature review (2019) (52)
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. (2017) (50)
Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. (2018) (49)
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. (2012) (48)
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer (2015) (47)
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data (2015) (47)
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. (2021) (47)
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. (2016) (45)
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management (2015) (45)
Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). (2011) (45)
Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity. (1990) (45)
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO (2018) (44)
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide (2013) (43)
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? (2012) (43)
Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram (2016) (43)
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. (2010) (43)
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer. (2018) (43)
Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma. (1989) (42)
Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. (2019) (41)
Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. (2018) (41)
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. (2018) (40)
Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC) (2012) (40)
Erlotinib after Failure of Gefitinib in Patients with Advanced Non-small Cell Lung Cancer Previously Responding to Gefitinib (2008) (40)
First‐line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors (2016) (39)
[Breast cancer in the early stage]. (2012) (39)
Trifluridine/Tipiracil plus Bevacizumab in Patients with Untreated Metastatic Colorectal Cancer Ineligible for Intensive Therapy: the Randomized TASCO1 Study. (2020) (39)
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer (2019) (38)
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study (2018) (38)
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial. (2013) (37)
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer (2020) (37)
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer (2009) (36)
Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms. (2013) (36)
Clinical impact of anti‐epidermal growth factor receptor monoclonal antibodies in first‐line treatment of metastatic colorectal cancer (2012) (36)
Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment (2008) (35)
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. (2009) (35)
Oral doxifluridine in elderly patients with metastatic colorectal cancer: a multicenter phase II study. (1994) (35)
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. (2012) (34)
Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. (2013) (33)
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients (2019) (33)
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. (2012) (33)
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy (2008) (32)
Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration‐resistant prostate cancer patients (2014) (32)
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. (2017) (32)
LBA-05Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer (2015) (31)
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients (2015) (31)
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study) (2016) (31)
Suramin in combination with weekly epirubicin for patients with advanced hormone‐refractory prostate carcinoma (1999) (31)
Genitourinary tumors, non-prostate (2012) (31)
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan (2014) (30)
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. (2013) (30)
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY). (2013) (30)
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials (2020) (30)
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer (2017) (29)
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab (2013) (29)
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. (2015) (29)
Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months (2017) (29)
FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group (2008) (28)
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation (2018) (28)
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial. (2019) (28)
METRONOMIC CYCLOPHOSPHAMIDE IN ELDERLY PATIENTS WITH ADVANCED, CASTRATION‐RESISTANT PROSTATE CANCER (2010) (28)
MRI tumor volume reduction rate vs tumor regression grade in the pre-operative re-staging of locally advanced rectal cancer after chemo-radiotherapy. (2015) (27)
Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. (2011) (27)
Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer (2012) (27)
Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge (2020) (27)
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer (2014) (27)
Tumor targeting by intra-arterial infusion of 5-[123I]iodo-2'-deoxyuridine in patients with liver metastases from colorectal cancer. (1996) (27)
The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.). (2006) (27)
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. (2006) (27)
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab (2013) (27)
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. (2018) (27)
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group (2017) (26)
Correlation of CDA , ERCC 1 , and XPD Polymorphisms with Response and Survival in Gemcitabine / Cisplatin ^ Treated Advanced Non ^ Small Cell Lung Cancer Patients (2008) (26)
Improved Analysis of 5-Fluorouracil and 5,6-Dihydro-5-Fluorouracil by HPLC With Diode Array Detection for Determination of Cellular Dihydropyrimidine Dehydrogenase Activity and Pharmacokinetic Profiling (2005) (26)
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients (2015) (26)
Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review. (2014) (26)
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). (2003) (26)
Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaks. (1996) (26)
Future strategies and adjuvant treatment of gastric cancer. (2003) (25)
Rapsody: randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α 2A (IFN) in metastatic renal cell carcinoma (MRCC). GOIRC study 0681 (2007) (25)
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients (2016) (25)
Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP”trial by the Gruppo Oncologico Nord Ovest (GONO). (2013) (25)
Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing. (2010) (24)
Limited sampling model for the analysis of 5‐fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer (2002) (24)
A Model of a Zebrafish Avatar for Co-Clinical Trials (2020) (24)
Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. (1996) (24)
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. (2014) (24)
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer (2009) (24)
Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward (2016) (24)
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? (2010) (23)
Application of the ESR iGuide clinical decision support system to the imaging pathway of patients with hepatocellular carcinoma and cholangiocarcinoma: preliminary findings (2020) (23)
A Randomized Phase III Study Evaluating the Continuation of Bevacizumab (BV) Beyond Progression in Metastatic Colorectal Cancer (MCRC) Patients (PTS) Who Received BV as Part of First-Line Treatment: Results of the Bebyp Trial by the Gruppo Oncologico Nord Ovest (GONO) (2012) (23)
Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC. (2019) (23)
Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer. (2017) (23)
A Phase I and Pharmacokinetic Study of Irinotecan Given as a 7-Day Continuous Infusion in Metastatic Colorectal Cancer Patients Pretreated with 5-Fluorouracil or Raltitrexed (2004) (23)
Palliative treatment of unresectable metastatic colorectal cancer (2010) (23)
Biweekly irinotecan, oxaliplatin, and infusional 5-FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized, phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) (2006) (22)
Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial (2017) (22)
Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells. (1997) (22)
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. (2017) (22)
Androgen receptor (AR) splice variant 7 and full‐length AR expression is associated with clinical outcome: a translational study in patients with castrate‐resistant prostate cancer (2019) (22)
Capecitabine and Mitomycin c May be an Effective Treatment Option for Third-line Chemotherapy in Advanced Colorectal Cancer (2006) (22)
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (2017) (22)
Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. (2015) (21)
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand–Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib (2018) (21)
Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). (2019) (21)
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer. (2020) (21)
Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. (2019) (21)
Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer. (2006) (21)
Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study (2020) (21)
Metronomic Chemotherapy for Metastatic Prostate Cancer (2010) (21)
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (2018) (21)
Infusions of Fluorouracil and Leucovorin: Effects of the Timing and Semi-Intermittency of Drug Delivery (1999) (20)
Continuous-infusion 5-fluorouracil in metastatic colorectal cancer patients pretreated with bolus 5-fluorouracil: clinical evidence of incomplete cross-resistance. (1994) (20)
Immune Checkpoint Inhibitors in Esophageal Cancers: Are We Finally Finding the Right Path in the Mist? (2020) (20)
Different effect of benzylacyclouridine on the toxic and therapeutic effects of azidothymidine in mice (1990) (20)
Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. (2012) (20)
TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial. (2016) (19)
A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab (2017) (19)
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients (2015) (19)
Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine (2020) (19)
Should oncologists be aware in their clinical practice of KRAS molecular analysis? (2011) (19)
Suramin in Combination with 5-Fluorouracil (5-FU) and Leucovorin (LV) in Metastatic Colorectal Cancer Patients Resistant to 5-FU+LV-Based Chemotherapy (1998) (19)
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer. (2019) (19)
Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial. (2013) (19)
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab (2017) (18)
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. (2020) (18)
LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO (2021) (18)
Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients. (2013) (18)
Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions. (2018) (18)
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. (2020) (18)
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. (2012) (18)
Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. (2014) (18)
Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II DOCETUX study) (2008) (18)
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials (2017) (18)
First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design. (2020) (18)
Impact of a supportive care service for cancer outpatients: management and reduction of hospitalizations. Preliminary results of an integrated model of care (2016) (18)
Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer (2020) (17)
Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients (2009) (17)
Results of a Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (CORRECT) of Regorafenib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients with Metastatic Colorectal Cancer (MCRC) who have Progressed after Standard Therapies (2012) (17)
Time course of regorafenib-associated adverse events in the phase III CORRECT study. (2013) (17)
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. (2014) (17)
397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study (2020) (17)
Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine‐based chemotherapy. A phase II Study (1995) (17)
Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation (2017) (16)
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer (2014) (16)
Recombinant α-2a Interferon Plus Vinblastine in the Treatment of Metastatic Renal Cell Carcinoma (1989) (16)
Surgical resection of metastases (mts) after biweekly chemotherapy with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI) in initially unresectable metastatic colorectal cancer (MCRC). (2004) (16)
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer. (2008) (16)
Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches. (2011) (16)
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials (2018) (16)
First-line therapy for mCRC — the influence of primary tumour location on the therapeutic algorithm (2017) (16)
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report (2002) (15)
Liquid biopsy to predict benefit from rechallenge with cetuximab (cet) + irinotecan (iri) in RAS/BRAF wild-type metastatic colorectal cancer patients (pts) with acquired resistance to first-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. (2018) (15)
Biochemical modulation by 5-fluorouracil and 1-folinic acid of tumor uptake of intra-arterial 5-[123I]iodo-2'deoxyuridine in patients with liver metastases from colorectal cancer. (1996) (15)
KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients. (2009) (15)
Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality. (2019) (15)
Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature. (2016) (15)
Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer (2004) (15)
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer (2009) (15)
Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis. (2017) (15)
Dissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy. (2014) (15)
Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study (1999) (15)
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. (2021) (15)
AR-V7 detection in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer (2016) (14)
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study (2020) (14)
Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer. (2017) (14)
Time course of regorafenib-associated adverse events in the phase III CORRECT study (2013) (14)
CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC). (2017) (14)
FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO) (2010) (14)
O-0022RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF TAS-102 VS. PLACEBO, WITH BEST SUPPORTIVE CARE (BSC), IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) REFRACTORY TO STANDARD THERAPIES (RECOURSE) (2014) (14)
Faithful markers of circulating cancer stem cells: is CD133 sufficient for validation in clinics? (2011) (14)
2139 CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy (2015) (13)
KRAS Early Testing: Consensus Initiative and Cost-Effectiveness Evaluation for Metastatic Colorectal Patients in an Italian Setting (2014) (13)
Electrochemotherapy and its controversial results in patients with head and neck cancer. (2014) (13)
Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases (2016) (13)
Second-line treatment for non-small-cell lung cancer: one size does not fit all. (2010) (13)
FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial (2016) (13)
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. (2017) (13)
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib (2020) (13)
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. (2019) (13)
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas. (2017) (13)
EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. (2008) (13)
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group. (2015) (13)
TAS-102 versus placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial. (2015) (12)
Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer. (2009) (12)
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First‐line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study (2018) (12)
First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first? (2008) (12)
Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer (2020) (12)
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer (2019) (12)
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients (2016) (12)
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. (2019) (12)
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study (2017) (12)
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment (2017) (12)
Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. (2018) (12)
The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis (2020) (12)
Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study. (2009) (12)
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. (2019) (12)
Pharmacokinetic Optimisation of the Treatment of Cancer with High Dose Zidovudine (1998) (12)
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma. (1994) (12)
TAS-102 for the treatment of metastatic colorectal cancer (2015) (11)
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients (2014) (11)
Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer. (2013) (11)
Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications (2020) (11)
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. (2015) (11)
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer (2015) (11)
Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase IIIb CONSIGN trial. (2016) (11)
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. (2020) (11)
Impact on Survival of Timing and Duration of Adjuvant Chemotherapy in Radically Resected Gastric Cancer (2016) (11)
Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO. (2016) (11)
Robotic-assisted surgery for colorectal liver metastasis: A single-centre experience (2020) (11)
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients? (2019) (11)
FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials. (2020) (11)
Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant alpha 2b-interferon. (1996) (11)
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. (2021) (11)
Cholinergic toxic syndrome by the anticancer drug irinotecan: Acetylcholinesterase does not play a major role (2002) (11)
Prognostic Effect of Adenosine‐related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab‐based Chemotherapy (2019) (11)
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation (2006) (11)
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients. (2010) (10)
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. (2009) (10)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): Updated survival results and final molecular subgroups analyses. (2015) (10)
BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database. (2021) (10)
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study (2019) (10)
Integrated safety summary for trifluridine/tipiracil (TAS-102) (2018) (10)
Phase II study of neoadjuvant chemotherapy with modified FOLFOXIRI in borderline resectable or unresectable stage III pancreatic cancer. (2013) (10)
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis (2016) (10)
A model of Zebrafish Avatar for co-clinical trials (2019) (10)
Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients. (2009) (10)
Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (mCRC). (2014) (10)
Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment. (2011) (10)
Alpha‐2B‐interferon plus floxuridine in metastatic renal cell carcinoma a phase I‐II study (1993) (9)
Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer. (2015) (9)
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. (2020) (9)
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab (2020) (9)
Folfoxiri plus Bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients. (2012) (9)
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study (2019) (9)
Biomarkers and Response to Bevacizumab—Letter (2014) (9)
Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials (2016) (9)
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. (2019) (9)
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study (2018) (9)
Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer. (1996) (9)
Breast cancer, locally advanced and metastatic (2012) (9)
O-0026FOLFOXIRI/BEVACIZUMAB VERSUS FOLFIRI/BEVACIZUMAB AS FIRST-LINE TREATMENT IN UNRESECTABLE METASTATIC COLORECTAL CANCER: RESULTS OF PHASE III TRIBE TRIAL BY GONO GROUP (2013) (9)
Pharmacoepigenetics in gastrointestinal tumors: MGMT methylation and beyond. (2016) (9)
Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab (2016) (9)
LBA13PHASE III RECOURSE TRIAL OF TAS-102 VS. PLACEBO, WITH BEST SUPPORTIVE CARE (BSC), IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) REFRACTORY TO STANDARD THERAPIES (2014) (9)
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? (2020) (9)
L32Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients (2015) (9)
Correlation of cytidine deaminase (CDA), xeroderma pigmentosum group D (XPD) and excision repair cross-complementing 1 (ERCC1) genes single nucleotide polymorphisms (SNPS) with response and survival in gemcitabine/cisplatin treated advanced non-small-cell lung cancer (NSCLC) patients (2007) (9)
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation (2021) (9)
Single nucleotide polymorphisms in the IGF‐IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE‐3 trial (2017) (9)
Immune profiling of deficient mismatch repair colorectal cancer (dMMR CRC) tumor microenvironment reveals different levels of immune system activation. (2020) (8)
Onset of neutropenia as an indicator of treatment response in the phase III RECOURSE trial of TAS-102 vs placebo in patients with metastatic colorectal cancer. (2016) (8)
Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients (2021) (8)
Correlation of insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan. (2009) (8)
Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration. (1987) (8)
Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial (2016) (8)
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO (2020) (8)
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study (2021) (8)
FOLFOXIRI and bevacizumab for metastatic colorectal cancer. (2015) (8)
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. (2012) (8)
TRIBE2: A phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts). (2018) (8)
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin- and irinotecan-based treatment in patients with metastatic colorectal cancer (2018) (8)
PNN and KCNQ1OT1 Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients (2020) (8)
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: current evidence, advances, and future perspectives (2021) (8)
First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study (2008) (8)
The impact of cetuximab on the gemcitabine/cisplatin combination in first-line treatment of EGFR-positive advanced pancreatic cancer (APC): A randomized phase II trial of GISCAD (2007) (8)
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. (2020) (8)
Evaluation of safety, immunogenicity, and preliminary efficacy of PolyPEPI1018 off-the-shelf vaccine with fluoropyrimidine/bevacizumab maintenance therapy in metastatic colorectal cancer (mCRC) patients. (2020) (8)
Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable mCRC. (2019) (8)
Monitoring clonal evolution and resistance to EGFR blockade in the blood of metastatic colorectal cancer patients (2016) (8)
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients. (2020) (8)
Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO). (2005) (8)
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin‐based chemotherapy in patients with metastatic colorectal cancer (2017) (8)
Moving-strip abdomino-pelvic radiotherapy after cis-platinum-based chemotherapy and second-look operation. A feasibility study in advanced ovarian cancer. (1988) (7)
Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies. (1994) (7)
PML as a potential predictive factor of oxaliplatin/fluoropyrimidine‐based first line chemotherapy efficacy in colorectal cancer patients (2012) (7)
Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m) (2016) (7)
Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients. (2017) (7)
Evaluation of the ovarian cancer antigen, Ca-125, as a tumor marker. (1989) (7)
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients (2016) (7)
A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients (2012) (7)
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS / BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis (2021) (7)
Supportive treatment for hematologic toxicities in the phase 3 RECOURSE trial of TAS-102 vs placebo with best supportive care in patients with metastatic colorectal cancer. (2016) (7)
Cisplatin and 5-Fluorouracil in Advanced and Recurrent Cervical Cancer (1988) (7)
Dedicated supportive care team at the oncology unit: a model of simultaneous care for cancer patients (2014) (7)
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. (2009) (7)
Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study. (2018) (7)
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable (2019) (7)
Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): Interim analysis from the prospective, observational CORRELATE study. (2017) (7)
5-Fluorouracil Administered as a 48-Hour Chronomodulated Infusion in Combination with Leucovorin and Cisplatin: A Randomized Phase II Study in Metastatic Colorectal Cancer (2001) (7)
PD-0034POPULATION PHARMACOKINETICS ANALYSIS OF REGORAFENIB AND ITS ACTIVE METABOLITES FROM THE PHASE III CORRECT STUDY OF METASTATIC COLORECTAL CANCER (2013) (7)
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. (2021) (6)
Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. (2021) (6)
Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients? (2009) (6)
Prolonged gemcitabine infusion in advanced non-small-cell lung cancer with stable disease after gemcitabine 30-min infusion. (2006) (6)
Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer (2005) (6)
Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. (2010) (6)
Postoperative Adjuvant Chemoradiotherapy for Rectal Cancer: Analysis of Acute and Chronic Toxicity (1997) (6)
CanStem303C trial: A phase III study of BBI-608 (napabucasin) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC) (2016) (6)
Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients (2021) (6)
Supportive care and not only palliative care in the route of cancer patients (2013) (6)
gastrointestinal tumours, colorectalNintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study (2016) (6)
Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database. (2013) (6)
Oral Doxifluridine in Advanced Hepatocellular Carcinoma: A Phase II Study (2000) (6)
Updated results, multivariate and subgroups analysis confirm improved activity and efficacy for FOLFOXIRI versus FOLFIRI in the G.O.N.O. randomized phase III study in metastatic colorectal cancer (MCRC) (2007) (6)
Rechallenge with cetuximab + irinotecan in 3rd-line in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients with acquired resistance to 1st-line cetuximab+irinotecan: The phase II CRICKET study by GONO. (2017) (6)
KRAS and BRAF genotyping of synchronous colorectal carcinomas (2014) (6)
Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity. (2021) (6)
Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: Final results and translational analyses of the CRICKET study by GONO. (2018) (6)
Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. (1989) (6)
Review: Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer (2009) (6)
Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon. (2019) (6)
Gastrointestinal tumors, non-colorectal (2012) (6)
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients (2018) (6)
6113 BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients (2009) (6)
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment (2013) (6)
KRAS and BRAF mutational status and response to cetuximab combination therapy in advanced gastric cancer (GC) patients (2009) (6)
Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib. (2013) (6)
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. (2019) (6)
Genetic interaction of P 2 X 7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients (2015) (5)
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma (2010) (5)
Fixed dose rate (FDR) gemcitabine (G) and capecitabine (C) in patients with metastatic biliary tract cancer (BTC): Final results of phase II trial. (2009) (5)
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies (2021) (5)
Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen (2009) (5)
Safety and effectiveness of regorafenib (REG) in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: An interim analysis (IA) from the prospective, observational CORRELATE study. (2017) (5)
Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer (2015) (5)
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. (2021) (5)
Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (MCRC): Overall Survival Update (2012) (5)
Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer (2007) (5)
RECOURSE trial: Performance status at discontinuation in patients receiving trifluridine/tipiracil (TAS-102) (2016) (5)
Early tumor shrinkage (ETS) and deepness of response (DoR) to predict progression-free, postprogression, and overall survival: Results from the phase III TRIBE trial. (2014) (5)
Pharmacodynamic biomarkers in metronomic chemotherapy: multiplex cytokine measurements in gastrointestinal cancer patients (2020) (5)
Outcomes by tumor location in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): Final analysis from the prospective, observational CORRELATE study. (2019) (5)
Outcome of initially unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases (mts) (2008) (5)
Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. (2019) (5)
Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based treatment in advanced colorectal cancer (2008) (5)
E13Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months (2015) (5)
Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib (2013) (5)
Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. (2014) (5)
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients (2019) (5)
Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study. (2019) (5)
E46Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial) (2015) (5)
Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group. (2014) (5)
Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): Final results from the prospective, observational CORRELATE study. (2018) (5)
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients (2018) (5)
Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer (2020) (5)
Rectal versus left-sided colon cancers: Clinicopathological differences observed in a pooled analysis of 4,182 patients enrolled to 8 clinical trials from the ARCAD database. (2017) (5)
Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO (2019) (5)
Atypical RAS Mutations in Metastatic Colorectal Cancer. (2019) (5)
A phase I study of PolyPEPI1018 vaccine plus maintenance therapy in patients with metastatic colorectal cancer with a predictive biomarker (OBERTO). (2019) (5)
PD-025RECOURSE trial: impact of adverse events on quality of life and duration of TAS-102 (trifluridine and tipiracil) treatment (2016) (4)
Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival. (2021) (4)
Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"? (2010) (4)
Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer (2011) (4)
Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts). (2017) (4)
Moving‐Strip Abdomino‐Pelvic Radiotherapy After cis-Platinum‐Based Chemotherapy and Second‐Look Operation A Feasibility Study in Advanced Ovarian Cancer (1988) (4)
A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice (2018) (4)
Refractory neuroendocrine tumor—response to liposomal doxorubicin and capecitabine (2009) (4)
Intrahepatic Chemotherapy with Floxuridine, Leucovorin and Dexamethasone in Continuous Infusion and Mitomycin-c Bolus in Unresectable Hepatic Metastases from Colorectal Cancer: A Phase II Study (1999) (4)
O-0007SUBGROUP ANALYSES IN RAS MUTANT, BRAF MUTANT AND “ALL WT” METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FOLFOXIRI PLUS BEVACIZUMAB (BEV) OR FOLFIRI PLUS BEV IN THE TRIBE STUDY (2014) (4)
An EZH 2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients (2012) (4)
Prognostic value of isolated peritoneal versus other metastatic sites in colorectal cancer (CRC) patients treated by systemic chemotherapy: Findings from 9,265 pts in the ARCAD database. (2016) (4)
Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. (2020) (4)
Risk for developing brain metastases from colorectal cancer in long-term survivors with lung metastases and KRAS mutations. (2013) (4)
DPYD and UGT 1 A 1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (2018) (4)
Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right? (2010) (4)
Regional pharmacokinetic selectivity of intraperitoneal cisplatin in ovarian cancer. (1988) (4)
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib (2019) (4)
Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses. (2019) (4)
Optimal approach to potentially resectable liver metastases from colorectal cancer (2008) (4)
Analysis of early tumor shrinkage and depth of response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or gemcitabine + nab-paclitaxel. (2018) (4)
The Winding Roadmap of Biomarkers Toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer (2018) (4)
4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study. (1987) (4)
Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial (2020) (4)
Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database. (2014) (4)
Consensus molecular subtypes and CRCassigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study. (2020) (4)
Abstract CT088: Efficacy of anti-EGFR rechallenge inRASandBRAFwt metastatic colorectal cancer: Clinical and translational results of the phase II CRICKET study by GONO (2018) (4)
Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study. (2022) (4)
Novel prognostic markers for epithelioid malignant pleural mesothelioma. (2017) (4)
Prospective evaluation of candidate snps of vegf/vegfr pathway in metastatic colorectal cancer patients treated with first-line folfiri plus bevacizumab (BV). (2012) (4)
Quality of life at baseline in the international open-label early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb). (2018) (4)
6115 VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) (2009) (4)
The role of clinicopathologic and molecular prognostic factors in the post-mastectomy radiotherapy (PMRT): a retrospective analysis of 912 patients. (2017) (4)
Gemcitabine in combination with capecitabine in metastatic breast carcinoma: A phase I-II study (2005) (4)
Modified FOLFOXIRI in Advanced Pancreatic Cancer (2012) (4)
Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial. (2014) (3)
O-011Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO (2016) (3)
VP11-2021: Trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study (2021) (3)
Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients (2008) (3)
Bevacizumab (BV) in combination with folfoxiri (Irinotecan, Oxaliplatin and Infusional 5FU/LV) as first-line treatment of metastatic colorectal cancer (mCRC): a phase II trial by the GONO GROUP (2009) (3)
Treatments (tx) after progression to first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and MOMA studies by GONO group. (2017) (3)
Small-Bowel Neuroendocrine Tumor and Retroperitoneal Fibrosis: Efficacy of Octreotide and Tamoxifen (2015) (3)
O-012Prognosis of lung metastases in patients with metastatic colorectal cancer: an ARCAD meta analysis (2016) (3)
Efficacy and safety results in patients with impaired renal and hepatic function in the RECOURSE trial. (2016) (3)
Duration of oxaliplatin‐based adjuvant chemotherapy in patients with Stage III or high‐risk Stage II resected colon cancer (2020) (3)
BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials. (2019) (3)
Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial. (2013) (3)
Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: Final analysis from the prospective, observational CORRELATE study. (2018) (3)
515PFOLFOXIRI PLUS BEVACIZUMAB (BV) OR PLUS ANTI-EGFR ANTIBODIES IN RAS AND BRAF WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS): ANALYSIS OF TUMOR RESPONSE. (2014) (3)
FOLFOXIRI-bevacizumab or FOLFOX-panitumumab in left-sided RAS/BRAF wild-type metastatic colorectal cancer patients: a propensity score-based analysis. (2020) (3)
O-006FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses (2015) (3)
6085 FOLFOXIRI (irinotecan, oxaliplatin, infusional 5FU/LV) vs FOLFIRI as first-line treatment of metastatic colorectal cancer (mCRC): updated results after 5 years follow up and risk-stratified analysis (2009) (3)
Cisplatin and cyclophosphamide in early epithelial ovarian carcinoma. (1987) (3)
Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer (2018) (3)
State of the art treatment for gastric cancer: future directions (2004) (3)
Analysis of single nucleotide polymorphisms (SNPs) of cytidine deaminase (CDA) and xeroderma pigmentosum group D (XPD) genes for the prediction of clinical response to gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) patients. (2006) (3)
Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target. (2009) (3)
Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database. (2015) (3)
Abstract 186: High-throughput microRNA (miRNAs) arrays unravel the prognostic role of miR211 in pancreatic cancer (2012) (3)
First-line treatment of metastatic colorectal cancer (MCRC) with folfoxiri (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the G.O.N.O. Group (2008) (3)
Economic evaluation of the cost of treating advanced gastric cancer (AGC) with capecitabine/cisplatin (XP) vs. 5-FU/cisplatin (FP) regimens in an Italian setting (2007) (3)
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers (2012) (3)
117 Oxaliplatin plus capecitabine in advanced neuroendocrine tumours (NETs): Is the new WHO classification applicable to daily practice? (2003) (3)
A Phase III Study of Oral Doxifluridine plus Radiotherapy in Radiosensitive Tumors of the Pelvic Region (1993) (3)
Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): A pooled analisys of TRIBE and TRIBE-2 studies by GONO (2019) (3)
Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study. (2017) (3)
CanStem303C trial: A Phase 3 Study of napabucasin (NAPA) in combination with 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI) in adult patients (pts) with previously treated metastatic colorectal cancer (mCRC) - Trial in progress. (2018) (3)
Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC? (2010) (3)
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. (2012) (3)
Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients. (2016) (3)
Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study (2006) (3)
Neoadjuvant Modified Folfoxiri in Locally advanced Pancreatic Cancer (2012) (3)
Phase II study of first-line treatment in metastatic colorectal cancer (MCRC) with GONO-FOLFOXIRI (Irinotecan, Oxaliplatin and Infusional 5FU/LV) plus Bevacizumab (2008) (3)
O-0027BEVACIZUMAB BEYOND PROGRESSION IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING A FIRST-LINE TREATMENT CONTAINING BEVACIZUMAB: UPDATE OF BEBYP TRIAL BY GONO (2013) (3)
6060 KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) (2009) (3)
Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study. (2017) (3)
The combination of capecitabine (C), irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) (2007) (3)
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? (2017) (3)
Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients. (2017) (3)
The role of PP2A variants to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials. (2021) (3)
Molecular Cancer Therapeutics Association of Polymorphisms in AKT 1 and EGFR with Clinical Outcome and Toxicity in Non – Small Cell Lung Cancer Patients Treated with Gefitinib (2010) (3)
Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer. (2021) (3)
Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study. (2017) (3)
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta‐analysis using TRIBE, MAVERICC and FIRE3 (2019) (2)
Phase II study of panitumumab (P) in combination with FOLFOXIRI as first-line treatment of metastatic colorectal cancer (mCRC): Activity in molecularly selected patients (pts). (2012) (2)
BRAF mutant metastatic colorectal cancers: new arrows in our quiver. (2019) (2)
Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab' (2013) (2)
Mucinous histology in advanced colorectal cancer patients treated with first-line irinotecan-and/or oxaliplatin-based chemotherapy (2008) (2)
Enhancer of zest homolog 2 (EZH2) expression in well and moderately differentiated pancreatic neuroendocrine tumor (pNET) (2016) (2)
ITACA-S (Intergroup trial of adjuvant chemotherapy in adenocarcinoma of the stomach) trial: comparison of a sequential treatment versus a 5-FU/LV regimen for radically resecate gastric cancer. Tolerability and feasibility of a randomized study (2010) (2)
Randomized phase III study of FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) vs FOLFIRI (irinotecan and 5FU/LV) as first-line treatment of metastatic colorectal cancer (MCRC): Subgroup and multivariate analysis (2007) (2)
478OEfficacy and safety of Sym004 in refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy: Results of a randomized phase II study (RP2S) (2017) (2)
EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis (2012) (2)
Radioembolization (SIRT) as a consolidation treatment in colorectal liver metastases after first line chemotherapy. (2016) (2)
mRNA expression levels of candidate genes and clinical outcome in mCRC patients treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. (2014) (2)
Analysis of hematologic adverse events (HeAEs) in trifluridine/tipiracil (FTD/TPI)-treated patients (pts) with or without renal/hepatic impairment (RI/HI): Pooled safety analyses from TAGS and RECOURSE. (2020) (2)
Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous histology. (2012) (2)
Different effect of benzylacyclouridine on the toxic and therapeutic effects of azidothymidine in mice. (1990) (2)
Not only chemotherapy in the second-line treatment of metastatic gastric cancer. (2014) (2)
PD-012Analysis of patients ≥75 years in the open-label phase 3b CONSIGN trial of regorafenib in previously treated metastatic colorectal cancer (mCRC) (2016) (2)
Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study. (2017) (2)
A new model of early supportive care and symptoms management: The experience of Pisa medical oncology. (2013) (2)
Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials. (2018) (2)
Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon (2019) (2)
Cancer pharmacogenomics: Germline DNA, tumor DNA, or both? (2007) (2)
Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months. (2015) (2)
Combination of trastuzumab, oxaliplatin, and docetaxel as first-line treatment in HER2-positive metastatic breast cancer patients: First-step results of a phase II trial (HOT trial). (2016) (2)
Impact of mucinous histology on prognosis for patients with radically resected stage Dukes B2 and C colon cancer: Preliminary results. (2009) (2)
Tumor targeting with 5-[123I]Iodo-2' Deoxyuridine infused into the hepatic artery of patients with liver metastases from colorectal cancer (1994) (2)
A42Incremental value of 3D echocardiography and two-dimensional speckle tracking in the early detection of cardiotoxicity linked to chemotherapy and trastuzumab in patients with HER-2 positive breast cancer (2015) (2)
Pharmacogenetic Concerns in Metastatic Colorectal Cancer Therapy (2012) (2)
Cytokinetic studies and treatment results of estrogens followed by chemotherapy in locally advanced (LABC) and metastatic (MBC) human breast cancer (1986) (2)
518PFOLFOXIRI WITH OR WITHOUT BEVACIZUMAB (BEV) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): A PROPENSITY SCORE-BASED ANALYSIS. (2014) (2)
2150 Low rates of hospitalizations with TAS-102 in the European (EU) subregion of the Phase 3 RECOURSE trial in patients (pts) with metastatic colorectal cancer (mCRC) (2015) (2)
5-Fluorouracil Administered as a 48-Hour Semiintermittent Infusion in Combination With Leucovorin, Cisplatin and Epirubicin: Phase II Study in Advanced Gastric Cancer Patients (2004) (2)
PP 22 Analysis of HER-3, insulin-growth factor-1 (IGF-1), nuclear factor k-B (NF-kB) and epidermal growth factor receptor (EGFR) gene copy number (GCN) in the prediction of clinical outcome for K-RAS wild type colorectal cancer patients receiving irinotecan–cetuximab (2011) (2)
Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer (2019) (2)
Integrated safety summary (ISS) for trifluridine/tipiracil (TAS-102) (2016) (2)
1711P SARS-CoV-2 infection in prostate cancer patients: Data from a high-incidence area in Italy (2020) (2)
Double 5‐Fluorouracil Modulation with Folinic Acid and Recombinant Alpha‐2B‐Interferon: A Phase I‐II Study in Metastatic Colorectal Cancer Patients (1994) (2)
Abstract 784: Pharmacodynamic biomarkers in metronomic chemotherapy: Multiplex cytokine measurements in gastrointestinal cancer patients (2017) (2)
Let-7a microRNA levels in KRAS-mutated colorectal carcinomas determine survival differences in patients treated with anti-EGFR. (2011) (2)
Cisplatin and carboplatin in combination chemotherapy for advanced ovary cancer. (1989) (2)
Tumor mutational load, microsatellite instability and actionable mutations in metastatic colorectal cancer: Results from the TRIBE2 study. (2020) (2)
Correlation of BRAF wild-type status (WT) in primary colorectal tumors with BRAF status in related metastatic sites: Implications for treatment with anti-EGFR antibodies (2010) (2)
Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer. (2008) (2)
C03Brain and pancreatic metastases: a clinico-pathological comparison of various facets of the tumor heterogeneity in renal cell carcinoma_The BRAVE project (2016) (2)
INFUSION OF 5-[I-123]IODO-2'-DEOXYURIDINE INTO THE HEPATIC-ARTERY OF PATIENTS WITH LIVER METASTASES FROM COLORECTAL-CANCER (1994) (2)
Genetic variants involved in the cGAS-STING pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials. (2021) (2)
PLS. plenary session (2012) (2)
Do we need biopsies of metastases for colorectal cancer patients? (2009) (2)
Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients (2021) (2)
Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients (2020) (2)
Adjuvant Chemoradiotherapy (Gemcitabine-based) in Pancreatic Adenocarcinoma: The Pisa University Experience (2017) (2)
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? : [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 (2017) (2)
6081 Bevacizumab (BV) in combination with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in metastatic colorectal cancer (MCRC): updated results of a phase II G.O.N.O. trial (2009) (2)
Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN) (2021) (2)
Oligometastatic colorectal cancer: Prognostic implications of tumor load, role of locoregional treatments, and of first-line therapy intensification—A pooled analysis of TRIBE and TRIBE2 studies by GONO. (2020) (2)
Does bevacizumab plus chemotherapy matter in metastatic colorectal cancer patients with mucinous histology? A multicenter, retrospective analysis on 685 patients. (2017) (2)
Magnitude of benefit of the addition of bevacizumab (BEVA) to first-line chemotherapy (CT) for advanced/metastatic colorectal cancer (MCRC): Meta-analysis of randomized clinical trials. (2009) (1)
Clinical and economic effect of administration of red blood product transfusions in an outpatient supportive care cancer service. (2020) (1)
Females versus males: Clinical features and outcome differences in large molecularly selected cohort of mCRC patients. (2016) (1)
Pre-treatment EGFR-T790M subclones in lung adenocarcinoma harboring activating mutation of EGFR: A positive prognostic factor for survival? (2018) (1)
P-0221 Folfoxiri Plus Bevacizumab as First-Line Treatment of Braf Mutant Metastatic Colorectal Cancer Patients (2012) (1)
F01*New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC) (2015) (1)
[Colorectal cancer: irinotecan in combination with newer drugs]. (2001) (1)
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). (2013) (1)
Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade (2021) (1)
Loss of PTEN expression in colorectal cancer (CRC) metastases (mets) but not in primary tumors predicts lack of activity of cetuximab plus irinotecan treatment (2008) (1)
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO (2021) (1)
PD-022FOLFOXIRI as primary treatment for locally advanced unresectable pancreatic cancer (LAPC): a prospective study (2016) (1)
Prognostic factors for efficacy of Ipilimumab used after anti-PD1 and/or BRAF+MEK inhibitors in melanoma patients: An Italian melanoma intergroup study (2019) (1)
Abstract 1342: Polymorphisms in genes involved in mitophagy pathway predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE3 phase III trials (2019) (1)
CCL2 polymorphism as a predictive marker for bevacizumab (Bev) in combination with FOLFIRI as first-line treatment in metastatic colorectal cancer (mCRC) patients (pts). (2014) (1)
Early magnesium modifications as a surrogate markers of efficacy of cetuximab-based anticancer treatment in KRAS wild-type colorectal cancer patients. (2010) (1)
Attrition bias: Does the benefit of targeted agents (TA) increase the more we search for a selection biomarker? Meta-regression analysis of randomized clinical trials (RCTs) in advanced non-small cell lung and colorectal cancer (NSCLC/CRC). (2011) (1)
Personalized Management of Colorectal Cancer (2013) (1)
FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: Final results of the phase II randomized MOMA trial by GONO. (2018) (1)
Variations of circulating KRAS amount as a biomarker to monitor chemotherapy response in pancreatic cancer. (2017) (1)
3022 POSTER Long-term outcome of unresectable metastatic colorectal cancer (MCRC) patients (pts) treated with first-line FOLFOXIRI followed by R0 surgical resection of metastases (2007) (1)
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. (2022) (1)
Expression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical response to CDK4/6 inhibitors in breast cancer. (2018) (1)
Longitudinal evaluation of angiogenesis-related circulating biomarkers during second-line treatment with paclitaxel and ramucirumab in advanced gastroesophageal cancer. (2019) (1)
Evaluation of lesion-based response at 12 weeks (LBR12) of treatment (Rx) in metastatic colorectal cancer (mCRC): Findings from 9,092 patients (pts) in the ARCAD database. (2018) (1)
Long-term outcome of unresectable metastatic colorectal cancer: does “adjuvant” chemotherapy play a role after resection? (2009) (1)
Effect of genetic variation on overall survival in a clinical trial of metastatic colorectal cancer (mCRC). (2015) (1)
Treatments (tx) after progression to first-line FOLFOXIRI + bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO (2019) (1)
Receipt and survival outcomes by age following second-line therapy for metastatic CRC (mCRC): Analysis of 5,289 patients from the ARCAD Clinical Trials Program. (2020) (1)
the Modulation of Gemcitabine Activity Outcome and Pharmacologic Aspects Underlying Its Role in MicroRNA-21 in Pancreatic Cancer : Correlation with Clinical (2010) (1)
Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. (2011) (1)
Results of a comprehensive pharmacogenetic analysis of dihydropyrimidine dehydrogenase in patients treated with fluoropyrimidines and patterns of polymorphisms partially related to treatment tolerability. (2012) (1)
A47Inherited mutations in breast cancer susceptibility genes among a triple negative breast cancer cohort unselected for family history of breast cancer (2015) (1)
690PCLINICAL IMPACT OF FOLFIRINOX DOSE/SCHEDULE MODIFICATIONS (MFOLFORINOX) AND ADDITIONAL SUPPORTIVE MEASURES IN THE MANAGEMENT OF PANCREATIC CANCER (PDAC) PATIENTS (PTS). (2014) (1)
Management of Peritoneal Carcinomatosis With Cytoreductive Surgery Combined With Intraperitoneal Chemohyperthermia at a Novel Italian Center (2020) (1)
A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy (2014) (1)
Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients. (1994) (1)
Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase IIIb PRECONNECT study. (2018) (1)
Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). (2011) (1)
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells (2019) (1)
Rechallenge with cetuximab (cet) + irinotecan (iri) in 3rd-line in RAS and BRAF wt metastatic colorectal cancer (mCRC) patients (pts) with acquired resistance to 1st-line cet + iri: the phase II CRICKET study by GONO. (2017) (1)
Proportional shortfall due to pancreatic cancer in Europe: Survival and quality of life analysis based on a systematic review. (2014) (1)
Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies. (2019) (1)
Detailing the ultrastructure’s increase of prion protein in pancreatic adenocarcinoma (2021) (1)
P-550 Prolonged gemcitabine infusion (GMCpi) alone or in combination with cisplatin in advanced NSCLC patients with stable disease (SD) after two courses of chemotherapy (CT) containing gemcitabine 30-minutes infusion (GMC) (2003) (1)
P1.15-10 Trabectedin Has Limited Clinical Activity in Pretreated Patients with Pleural Mesothelioma (2019) (1)
3063 POSTER Capecitabine (C), in combination with irinotecan (I) and oxaliplatin (O) (XELOXIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a pilot study by the Gruppo Oncologico Nord-Ovest (G.O.N.O.) (2007) (1)
31 Second line chemotherapy with docetaxel in elderly advanced NSCLC patients: A phase II study (2003) (1)
Prospective study of EGFR intron 1 CA tandem repeats to predict factor benefit from cetuximab and irinotecan. (2012) (1)
P-219 Clear cell variant of hepatocellular carcinoma (HCC-CC): A single-center observational study of an uncommon subtype (2020) (1)
TUMOR TARGETING WITH 5-[I-123]IODO-2'-DEOXYURIDINE INFUSED INTRAARTERIALLY IN COLON-CANCER PATIENTS WITH LIVER METASTASES (1994) (1)
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial (2023) (1)
2362 Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients (2015) (1)
Cancer Therapy : Clinical Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide , Celecoxib , and Dexamethasone in Advanced Hormone-refractory Prostate Cancer (2009) (1)
613TiPA PROSPECTIVE, OBSERVATIONAL TRIAL TO FURTHER ASSESS SAFETY AND EFFICACY OF REGORAFENIB IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) IN ROUTINE CLINICAL PRACTICE (CORRELATE). (2014) (1)
Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer. (2017) (1)
RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC). (2017) (1)
Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer. (2017) (1)
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). (2013) (1)
Impact of PIK3CA mutations and p95HER2 expression on the outcome of HER2-positive metastatic breast cancer patients treated with a trastuzumab-based therapy. (2012) (1)
Prognostic Value of CD133 Caused by Mutant K-Ras and B-Raf—Letter (2012) (1)
Optimization of biomarkers-based classification scores as progression-free survival predictors: an intuitive graphical representation (2018) (1)
Clinical and molecular landscape of metastatic colorectal cancer (mCRC) harboring ALK, ROS1, or NTRK 1, 2, 3 (NTRKs) rearrangements. (2017) (1)
O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study (2021) (1)
Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer (2019) (1)
Gastrointestinal tumors, colorectal (2012) (1)
Early magnesium modiﬁcations as a surrogate marker of efﬁcacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients (2011) (1)
Abstract 4819: MicroRNA-21 (miR-21) in pancreatic ductal adenocarcinoma (PDAC): Correlation with clinical outcome and pharmacological aspects underlying its role in the modulation of gemcitabine activity (2010) (1)
Prognostic relevance of lymph node metastases and adjuvant treatment for patients with invasive intraductal papillary mucinous neoplasms (IPMNs) of the pancreas (2010) (1)
In Pancreatic Adenocarcinoma Alpha-Synuclein Increases and Marks Peri-Neural Infiltration (2022) (1)
Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. (2021) (1)
A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy (2014) (1)
Impact of age on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies. (2019) (1)
A phase I and pharmacokinetic study of irinotecan given as a 7 days continuous infusion in metastatic colorectal cancer patients pretreated with 5-FU or raltitrexed (2001) (1)
P-158Radioembolization (SIRT) as a Consolidation Treatment in Colorectal Liver Metastases after First Line Chemotherapy: Efficacy Safety. (2016) (1)
D12TRUST: phase II trial of induction chemotherapy (CT) with FOLFOXIRI plus bevacizumab (BV) followed by chemo-radiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC) (2016) (1)
Docetaxel in combination with non pegylated liposome-encapsulated doxorubicin (MYOCET ®) for the treatment of metastatic breast cancer (MBC) patients: a phase II clinical study (2008) (1)
P-180Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients: a single institution retrospective cohort study (2015) (1)
Evaluation of safety, immunogenicity and preliminary efficacy of PolyPEPI1018 vaccine in subjects with metastatic colorectal cancer (mCRC) with a predictive biomarker (2019) (1)
O-0023 Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC) (2012) (1)
A59T-DM1 for HER2 positive advanced breast cancer: a single institution, “real life” experience (2015) (1)
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study (2022) (1)
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) (2008) (1)
Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): a phase II clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination (2006) (1)
Erratum: Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer (British Journal of Cancer (2004) 92 (24-29) DOI: 10.1038/sj.bjc.6602276) (2005) (1)
Polymorphism in cancer-associated fibroblasts (CAFs) related genes and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) enrolled in two independent randomized phase III trials: TRIBE and FIRE-3. (2018) (1)
Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer (2013) (1)
P-198Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib (2015) (1)
Rationale for Treatment of Metastatic Disease of the Liver (1999) (1)
BRAF and KRAS mutations in liver-resected metastatic colorectal cancer (mCRC) patients (pts). (2014) (1)
Resection of Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy with Modified FOLFIRINOX: A Prospective Phase II Study (2013) (1)
Nuclear factor-kb (NF-KB)tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer patients treated with cetuximab-irinotecan therapy (2007) (1)
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) (2008) (1)
SO-18 Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results according to duration of treatment from the phase IIIb, international, open-label, early-access PRECONNECT study (2021) (1)
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical and pharmacodynamic evaluation. (2006) (1)
Dedifferentiated liposarcoma: when eribulin can make the difference. (2019) (1)
Phase II study of neoadjuvant modified folfoxiri in locally advanced pancreatic cancer. (2012) (1)
The role of sidedness, EGFR gene copy number (GCN) and EGFR promoter methylation in RAS/BRAF wild type (WT) colorectal cancer (CRC) patients receiving irinotecan/cetuximab. (2017) (1)
Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX. (2017) (1)
The international open-label early-access study of trifluridine/tipiracil (TAS-102) in patients with pretreated metastatic colorectal cancer (phase IIIb). (2017) (1)
O-0010LONG-SURVIVORS WITH LUNG METASTASES AND KRAS MUTATIONS HAVE AN INCREASED RISK TO DEVELOP BRAIN METASTASES FROM COLORECTAL CANCER (2013) (1)
SO-20 Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study (2021) (1)
The Role of Metronomic Chemotherapy in the Treatment of Metastatic Colorectal Cancer Patients (2014) (1)
The effect of bevacizumab plus chemotherapy on the immunological profile of advanced colorectal cancer patients (2008) (1)
Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis. (2019) (1)
AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) (2019) (1)
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO (2020) (1)
An easy-to-use nomogram to predict overall survival (OS) at 6 months after initiation of FOLFIRINOX first-line chemotherapy in patients (pts) with metastatic pancreatic cancer (mPC). (2018) (1)
B12Enhancer of zeste homolog 2 (EZH2) expression in G1 -G2 Pancreatic Neuroendocrine Tumor (pNET) (2016) (1)
Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled analysis of 21 first-line trials in the ARCAD database. (2014) (1)
Histopathologic response to FOLFOXIRI plus bevacizumab of liver metastases from colorectal cancer. (2011) (1)
Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC (2014) (1)
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients. (2019) (1)
Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials. (2019) (1)
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. (2013) (1)
PD-0005PHASE II STUDY OF SINGLE AGENT CETUXIMAB IN KRAS G13D MUTANT METASTATIC COLORECTAL CANCER (MCRC) (2014) (1)
Second line chemotherapy after first line irinotecan, oxaliplatin and 5-FU/LV (FOLFOXIRI) in metastatic colorectal cancer (MCRC) patients (pts). (2004) (1)
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab. (2017) (1)
Pooled safety analysis from phase 3 studies of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC) and metastatic colorectal cancer (mCRC). (2019) (1)
Pharmacogenetic profiling for anti-epidermal growth factor receptor (EGFR) therapy in (pts) with refractory advanced colorectal cancer (ACRC) (2007) (1)
Safety and tolerability of regorafenib (REG) in Italian patients: Subgroup analysis of the phase III CORRECT study in metastatic colorectal cancer (mCRC). (2014) (0)
F51Adjuvant endocrine therapy in elderly patient in early Breast Cancer, a less toxic therapy, is it really true? A single institution, “real life” experience (2016) (0)
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer (2018) (0)
Nuclear factor kB (NF-kB) may predict efficacy of cetuximab therapy in EGFR-positive colorectal cancer (2007) (0)
ZEBRAFISH EMBRYO AS AVATAR OF PATIENTS WITH PANCREATIC CANCER: PRELIMINARY EXPERIENCE TOWARD A PERSONALIZED MEDICINE (2019) (0)
Polymorphisms in beta-defensin pathways and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI-bevacizumab in two randomized phase III trials. (2018) (0)
PIK3CA mutation in metastatic colorectal cancer (mCRC): Association with clinico-pathological features and outcome (2019) (0)
Common genetic variants in genes involved in the Hippo pathway: Novel biomarkers in metastatic colorectal cancer patients treated with irinotecan plus cetuximab. (2014) (0)
Adjuvant chemotherapy for radically resected biliary tract cancer: a retrospective analysis (2010) (0)
711 Intrahepatic chemotherapy with floxuridine (FUDR) L-leucovorin (LV), desametazone (D) in continuous infusion and bolus mytomicin C (MMC) in hepatic metastases from colorectal cancer: A phase II study (1995) (0)
Role of adjuvant chemotherapy in the treatment of radically resected biliary tract cancer: a single institution experience. (2012) (0)
RET rearrangements define an uncommon molecular subtype of metastatic colorectal cancer (mCRC). (2017) (0)
MICRORNA-21 FROM BENCH TO BEDSIDE AND BACK: A POTENTIAL MARKER OF CLINICAL OUTCOME AND A TARGET TO OVERCOME RESISTANCE TO GEMCITABINE IN PANCREATIC CANCER (2010) (0)
Exploratory analysis of circulating pro- and antiangiogenic factors in metastatic colorectal cancer (mCRC) patients, treated with GONO-FOLFOXIRI plus bevacizumab (BV). (2010) (0)
Resectable liver metastases from colorectal cancer: where we are now and where do we go from here? (2012) (0)
A phase II study of chronomodulated (CHR) 5-fluorouracil (5-FU) and leucovorin (LV) in combination with epirubicin (EPIDX)and Cis-Platin (CDDP) in the treatment of metastatic gastric carcinoma (MGC) (1997) (0)
262 First line simplified FOLFOXIRI in metastatic colorectal cancer (MCRC) patients (pts): results of a phse II study (2003) (0)
Correlation of early tumor shrinkage (ETS) and depth of response (DoR) with resectability in patients (pts) with unresectable locally advanced pancreatic cancer (LAPC) undergoing primary treatment with FOLFOXIRI. (2017) (0)
Evaluation of prognostic factors and of the role of adjuvant chemotherapy in patients with invasive carcinoma derived from intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. (2010) (0)
A pharmacogenetic interaction analysis of bevacizumab with paclitaxel in advanced breast cancer patients (2022) (0)
Modified folfoxiri in advanced pancreatic cancer. (2012) (0)
Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA counting. (2018) (0)
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer (2015) (0)
PD-009Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies (2016) (0)
P-583 Clinical parameters predictive of response in advance non-small-cell lung cancer (NSCLC) patients receiving gefitinib in am expanded access program (EAP) after failure of chemotherapy (2005) (0)
Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre (2019) (0)
L29Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense? (2015) (0)
2311 Evaluation of predictive factors of efficacy of Somatostatin Analogs (SSA) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): a single centre experience (2015) (0)
First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients (2009) (0)
1307 POSTER First-line chemotherapy with sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer (NSCLC) patients: a multicenter phase II study (2007) (0)
[Continuous versus intermittent infusion in chemotherapy of colorectal cancer]. (2001) (0)
Host geneticd variants in the insulin growth factor binding protein-3 impact on survival of patients with adanced gastric cancer treated with palliative chemotherapy (2010) (0)
A randomised phase II study of cetuximab plus gemcitabine/cisplatin combination in advanced pancreatic cancer (APC) (2007) (0)
Lung Progression After Resection for Invasive Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas (2012) (0)
Genetic variants in RNA binding protein (RBP) to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE, and MAVERICC trials. (2019) (0)
Bilateral Anterior Uveitis Following Zoledronic Acid Therapy In BreastCancer: A Case Report (2017) (0)
Current chemotherapy regimens in first and second line (2010) (0)
Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation (2008) (0)
Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first-line treatment in castration resistant prostate cancer (CRPC) patients (Pts). (2009) (0)
The impact of Tfh cell/ B cell pathway-related genetic variants in metastatic colorectal cancer patients with bevacizumab-based chemotherapy. (2018) (0)
AB076. P048. Microsatellite instability and tumor volume inversely affect early progression free survival in adjuvant setting of patients with pancreatic ductal adenocarcinoma: lights and shadows of molecular pathology and immunotherapy (2018) (0)
Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations (2008) (0)
Glucose metabolism enzymes gene expression analysis and selective metabolism advantage in the clinical progression of colorectal cancer (CRC) (2015) (0)
Abstract LB-238: Dissecting primary resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) inRASandBRAFwild-type (wt) metastatic colorectal cancer (mCRC) (2017) (0)
Capecitabine (C) in combination with irinotecan (I) and oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): preliminary results of a pilot study by Gruppo Oncologico Nord Ovest (G.O.N.O.) (2006) (0)
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer (2019) (0)
Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer. (2017) (0)
Clinicopathological factors influence diagnostic accuracy of clinical N staging for early gastric cancer. (2017) (0)
PP 92 Clinical and genetic characterization of dihydropyrimidine dehydrogenase deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele (2011) (0)
OP62 Polymorphisms in AKT1 and EGFR as possible new biomarkers of clinical outcome and toxicity in non-small-cell lung cancer patients treated with gefitinib (2009) (0)
L26Second-line chemotherapy after disease progression following first-line FOLFOXIRI in advanced pancreatic cancer patients (2015) (0)
Prognostic role of neutrophil-to-lymphocyte ratio (NLR) dynamics during first-line FOLFOXIRI in advanced pancreatic cancer (aPC). (2017) (0)
Abstract CT095: Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients (pts) bearing MGMT methylation (2018) (0)
Phase II clinical trial with pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of metronomic oral vinorelbine (V) and dexamethasone (D) in patients with advanced castration resistant prostate cancer (CRPC): preliminary clinical results (2010) (0)
Added to standard fluorouracil and leucovorin therapy, irinotecan increases colorectal cancer survival with few adverse effects (2001) (0)
bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials (2010) (0)
Optimizing the use of first-line chemotherapy in metastatic colorectal cancer patients with mucinous histology. A multicenter, retrospective, combined analysis on 897 patients. (2018) (0)
High activity and resection rate in molecularly selected patients with unresectable metastatic colorectal cancer (MCRC) treated with panitumumab (P) and folfoxiri as first-line therapy : a phase II study. (2012) (0)
Baseline characteristics in the international, open-label, early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb). (2018) (0)
BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases. (2018) (0)
P-308RAVELLO trial: Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (2015) (0)
Prognostic factors for patients with advanced gastric cancer receiving irinotecan, 5-fluorouracil (5-FU), and leucovorin (FOLFIRI) as salvage therapy after fluoropyrimidine/platinum-based chemotherapy: A retrospective analysis (2011) (0)
Bevacizumab (B) combined to chemotherapy for first-line treatment of elderly patients with advanced colorectal cancer (CRC): results from a large community-based Italian observational study. (2012) (0)
Functional characterization of EZH2 single nucleotide polymorphism and correlation of EZH2 expression with clinico-pathological and molecular parameters in colorectal (CRC) cancer samples. (2012) (0)
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management. (2015) (0)
Baseline Patient Characteristics in the International, Open-Label, Preconnect Study of Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer (PHASE-IIIB) (2018) (0)
531PNEUTROPHIL/LYMPHOCYTE RATIO AND PIASTRINOSIS CORRELATE WITH CLINICAL OUTCOME IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING REGORAFENIB. (2014) (0)
NOS2 polymorphisms in the prediction of benefit from FOLFIRI plus bevacizumab in mCRC patients enrolled in TRIBE trial. (2016) (0)
F43Neoadjuvant Chemotherapy among Breast Cancer subtypes: a single-institution retrospective study (2016) (0)
An everolimus treatment in metastatic pancreatic neuroendocrine cercinomas and metastatic gastrointestinal neuroendocrine carcinoma. (2012) (0)
SO-20 Consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study (2020) (0)
Genetic analysis of cytidine deaminase (CDA) for the prediction of response to chemotherapy and survival in advanced non-small-cell lung cancer (NSCLC) patients treated with gemcitabine (2006) (0)
A retrospective analysis of her-2 hyperexpression in gastric and gastroesophageal junction (gej). (2012) (0)
Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE. (2019) (0)
Adjuvant chemotherapy for resected biliary tract cancer: A retrospective analysis. (2011) (0)
In vivo immunological effects of anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer (MCRC) patients (2009) (0)
Folfiri as salvage therapy after fluoropyrimidine and platinum-based first-line chemotherapy for advanced gastric cancer: multivariate analysis of prognostic factors (2011) (0)
Pegfilgrastim to support chop-r chemotherapy administered every 14 days in the patients (pts) with aggressive b-cell non-hodgkin’s lymphoma (NHL) (2007) (0)
CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients. (2016) (0)
Prognostic factors for response to aminoglutethimide in breast cancer (1986) (0)
Clinical features and outcomes of pancreatic cancer patients evaluated for microRNAs as biomarkers of response to treatment during FOLFIRINOX therapy (2017) (0)
High-throughput exome array for identification of novel polymorphisms associated with clinical outcome in mCRC patients treated with first-line FOLFOXIRI/BEV versus FOLFIRI/BEV (TRIBE trial; NCT00719797). (2014) (0)
Phase II study of irinotecan, oxaliplatin and infusional 5FU/LV (GONO-FOLFOXIRI) plus bevacizumab (BV) as first-line treatment in metastatic colorectal cancer (MCRC) (2008) (0)
Phase II clinical trial with pharmacodynamic evaluation of docetaxel/prednisone plus metronomic cyclophosphamide and celecoxib as first line treatment in metastatic hormone refractory prostate cancer (MHRPC) (2008) (0)
Sequential use of treatment options in advanced renal cell carcinoma (RCC): a retrospective analysis of 42 cases. (2012) (0)
Conference Scene: Annual Meeting of the American Society of Clinical Oncology (2013) (0)
Impact of gender on the safety profile of chemotherapy plus bevacizumab in mCRC: A pooled analysis of TRIBE and TRIBE2 studies. (2019) (0)
6097 The recovery of circulating dendritic cells during anti-VEGF treatment is related to clinical outcome in advanced colorectal cancer patients (2009) (0)
Are anti-HER2 agents the best choice in metastatic breast cancer with an HER2 positive switch from primary tumour? A retrospective multi institution analysis of clinical-pathological characteristics and outcomes. (2017) (0)
Histopathologic response and growth patterns of colorectal cancer liver metastases (CRCLM) in patients treated with triplets plus bevacizumab (bev) or anti-EGFRs. (2017) (0)
Body mass index and impaired fasting blood glucose as predictive factor of efficacy in cetuximab-based colorectal cancer treatment. (2012) (0)
Safety and efficacy of non-pegylated liposomal doxorubicin (NPLD) in HER2 negative metastatic breast cancer (mBC) patients (PTS) as second-line (2L) and beyond: a restrospective single institution analysis. (2017) (0)
Cetuximab plus irinotecan in irinotecan-resistant elderly metastatic coloretal cancer patients: clinical outcome according to KRAS and BRAF mutational status (2010) (0)
AbstractAzidothymidine (AZT), 5-fluorouracil (5-FU) and l-folinic acid (FA): A pilot study in metastatic colorectal cancer (MCRC) (1994) (0)
PML as a potential predictive factor of efficacy of oxaliplatin based first line chemotherapy in colorectal cancer patients (2009) (0)
582 A phase I study of day 1 and 8 every three weeks docetaxel infusion (2003) (0)
3067 POSTER Irinotecan Metronomic Chemotherapy (MC) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation (2007) (0)
Pilot study of correlation between single nucleotide polymorphisms (SNPS) of pro-and anti-angiogenic genes and response to bevacizumab (BV) plus chemotherapy (CT) in patients with metastatic breast cancer (MBC) (2011) (0)
L48Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer (2015) (0)
Chemotherapy for Metastatic Invasive Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas (2012) (0)
Loss of PTEN expression in colorectal cancer (CRC) metastases (METS) predicts lack of activity of cetuximab plus irinotecan treatment (2008) (0)
Inhibition of acetylcholinesterase in patients receiving irinotecan (CPT-11) (2004) (0)
letters to the editor EZH2 polymorphism and beneﬁt from bevacizumab in colorectal cancer: another piece to the puzzle (2012) (0)
Zebrafish embryos as avatar of patients with pancreatic cancer: preliminary results of validation a new model toward personalized medicine (2020) (0)
KSR1 gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab. (2012) (0)
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients (2010) (0)
Genetic variant in the down syndrome candidate region 1 (DSCR1) gene: A novel biomarker in metastatic colorectal cancer. (2014) (0)
FDG-PET/CT (PET) in the early prediction of benefit from first-line chemotherapy plus bevacizumab (bev) in metastatic colorectal cancer (mCRC). (2013) (0)
Metastatic breast cancer: an analysis of prognostic factors in patients treated with aminoglutethimide. (1987) (0)
Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver limited metastatic colorectal cancer (mCRC). (2018) (0)
KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC: an analysis on circulating tumor DNA (2015) (0)
Should bevacizumab (B) be included in the first-line treatment of elderly patients with advanced colorectal cancer (CRC)? Results from a community-based Italian observational study. (2012) (0)
G1 A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma G2 Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma a retrospective single (2017) (0)
EP-1298: Stereotactic radiotherapy in oligometastatic patients with lung metastasis from colon-rectal cancer (2016) (0)
B10Mixed meta-analysis of treatment options for locally advanced oesophageal squamous-cell carcinoma (2016) (0)
Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: Independent actors or reciprocal drivers? A translational study by Meet-Uro group. (2018) (0)
Retrospective analysis of concomitant treatment with 3-dimensional conformal radiotherapy and temozolomide in high-grade glioma patients (2008) (0)
6082 Second-line treatments in patients with metastatic colorectal cancer progressed after first-line FOLFOXIRI (2009) (0)
Angiopoietin-2 early increase to predict benefit from regorafenib in metastatic colorectal cancer (mCRC) patients: The prospective REGOLAND study. (2021) (0)
Contents Vol. 91, 2016 (2016) (0)
L14Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (pts) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? (2015) (0)
Tumor characteristics, treatment modalities and clinical outcome in breast cancer (BC) patients (PTS) with 10 or more positive nodes. Results from the NORA study (2006) (0)
[Adjuvant chemotherapy with cisplatin and cyclophosphamide in FIGO I-II epithelial carcinoma of the ovary: preliminary results]. (1985) (0)
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). (2022) (0)
E08Prognostic significance of KRAS mutation rate in metastatic colorectal cancer patients (2015) (0)
3519 POSTER Cost of treating advanced gastric cancer (AGC) with capecitabine/cisplatin vs. 5-FU/cisplatin regimens: An economic evaluation from an Italian perspective (2007) (0)
Association of eNOS polymorphisms with clinical outcome in bevacizumab-treated breast cancer patients. (2014) (0)
Genetic variants of Pin1 to predict benefit from irinotecan and oxaliplatin based treatment in patients with metastatic colorectal cancer (mCRC). (2016) (0)
Baseline predictive factors for efficacy of anti-PD1 used in first line in melanoma patients: An Italian melanoma intergroup study. (2018) (0)
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data (2015) (0)
Report Congressuali: ASCO GI 2007 Gastrointestinal Cancers Symposium (2007) (0)
P2-314: First line chemotherapy with sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer (NSCLC) patients: a multicenter phase II study (2007) (0)
C21First Italian Multicentre Experience in using Ra-223 in patients with metastatic castration resistant prostate cancer (mCRPC) (2016) (0)
Genetic variants in the one-carbon metabolism pathway to predict outcome in patients with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials (2019) (0)
EGFR/KRAS-Germline mutation analyses in advanced non-small cell lung cancer (NSCLC) patients treated with Gefitinib/Erlotinib (2008) (0)
Infusional Chemotherapy in Colorectal Cancer (1997) (0)
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group (2017) (0)
Natural history of invasive intraductal papillary mucinous neoplasms (IPMNs) of the pancreas compared with sporadic pancreatic adenocarcinoma (PDAC) (2010) (0)
Alpha-2B-Interferon in metastatic + Floxuridine + renal carcinoma: a phase II study (1994) (0)
TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients. (2016) (0)
Ampullary adenocarcinomas: The immunohistochemical score of CDX2, CK7 and CK 20 identify pathological subtypes and their prognosis (2018) (0)
PGI15 - HEALTHCARE RESOURCE UTILIZATION (HCRU) IN METASTATIC OR UNRESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER PATIENTS RECEIVING SECOND-LINE TREATMENT (2018) (0)
A still missing piece of the FIRE-3 puzzle. (2016) (0)
Preliminary results from a phase II study of panitumumab (P) in combination with folfoxiri as first-line treatment of molecularly selected metastatic colorectal cancer (MCRC) patients (PTS) (2011) (0)
Abstract B049: Characterizing and targeting RET fusions-positive metastatic colorectal cancer (mCRC) (2018) (0)
Lights and shadows of molecular pathology and immunotherapy in adjuvant setting of patients with pancreatic ductal adenocarcinoma: Tumor volume and microsatellite instability inversely affect early progression free survival (2018) (0)
Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity? (2010) (0)
Double 5-FU modulation with folinic acid and recombinnant alfa2b-Interferon: a phase I-II study in metastatic colorectal cancer patients (1991) (0)
Optimal strategy to increase the respectability of liver/lung metastases (2008) (0)
Genetic variants in methylation and demethylation pathways to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/Bev: Data from TRIBE and FIRE-3 trials. (2018) (0)
Suramin in metastatic colorectal cancer patients pretreated with fluoropyrimidine-based chemotherapy: a phase II trial (1995) (0)
O-18 Tumor mutational load, microsatellite instability, BRCAness, and actionable alterations in metastatic colorectal cancer: Results from the TRIBE2 study (2020) (0)
Prognostic and predictive role of neutrophils/lymphocytes ratio in metastatic colorectal cancer: A retrospective analysis of the TRIBE study by Gono. (2017) (0)
Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis. (2019) (0)
Correlation of expression of TK1 in plasma-derived exosomes with clinical response to CDK4/6 inhibitors in breast cancer. (2018) (0)
Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer. (2017) (0)
Overall survival in intermediate-stage hepatocellular carcinoma (HCC) patients after first transarterial chemoembolization (TACE): Proposal of a new scoring system. (2015) (0)
P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab. (2018) (0)
Predictive role of a pharmacogenetic profiling in patients with advanced colorectal cancer (ACRC) treated with first-line, 5-fluorouracil/oxaliplatin chemotherapy (2006) (0)
228PPATTERN OF DIHYDROPYRIMIDINE DEHYDROGENASE GENETIC VARIANTS IN PATIENTS WITH VARIOUS DEGREES OF TOLERABILITY OF FLUOROPYRIMIDINE TREATMENT. (2014) (0)
D05FOLFOXIRI plus bevacizumab (bev) as upfront treatment for metastatic colorectal cancer (mCRC) patients (pts) with initially unresectable liver-limited disease (LLD) (2016) (0)
1045P Comparison between first-line target therapy and immunotherapy in different prognostic categories of BRAF mutant metastatic melanoma patients (2021) (0)
Genetic variants in immunogenic cell death (ICD) relating genes to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE and MAVERICC trials. (2020) (0)
1429PTHERAPEUTIC DRUG MONITORING OF IMATINIB IN GIST PATIENTS. (2014) (0)
B07An Italian Cost-Effectiveness Analysis of Paclitaxel Albumin (nab®-paclitaxel) + Gemcitabine vs Gemcibatine alone for Metastatic Pancreatic Cancer Patients: The APICE Study (2016) (0)
A multicenter phase II study of sequential gemcitabine followed by docetaxel in elderly advanced non-small cell lung cancer (NSCLC) patients from the Polmone Toscano Group (POLTO) (2006) (0)
Fixed-Dose Rate Gemcitabine Plus Capecitabine as Second-Line Treatment for Metastatic Pancreatic Cancer Patients Pretreated with Oxaliplatin (2012) (0)
F32Feasibility and efficacy of 223Ra-dichloride (223Ra) to treat bone metastases in patients (pts) with castration resistant prostate cancer (mCRPC) (2015) (0)
K-RAS status in primary colorectal tumours correlate with K-RAS status in related metastatic sites: implications for treatment with anti-EGFR antibodies in clinical setting (2008) (0)
5 FU + Irinotecan (2003) (0)
FLOaTing toward new standards in locally advanced resectable gastroesophageal cancer. (2019) (0)
Clinical impact of neutropenia and febrile neutropenia in mCRC pts treated with FOLFOXIRI/bevacizumab (bev): A pooled analysis of TRIBE and TRIBE2 studies. (2019) (0)
Validation of cost-effectiveness of trifluridine/tipiracil versus best supportive care and regorafenib for previously treated metastatic colorectal cancer in the UK using phase IIIb PRECONNECT early access clinical trial data in the real world setting. (2019) (0)
Genetic variants involved in the lipid metabolism pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC trials. (2021) (0)
Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial (2019) (0)
Chemotherapy without monoclonal antibodies in the treatment of metastatic colorectal cancer: Role of Triplets (2008) (0)
RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC (2021) (0)
P-0263 Prospective Study of Egfr Intron 1 CA Tandem Repeats as Predictive Factor of Benefit from Cetuximab and Irinotecan (2012) (0)
Chemotherapy intensification (2007) (0)
Predictive biomarkers of response in colorectal cancer (2011) (0)
Folfoxiri compared to Folfiri as first-line treatment of metastatic colorectal cancer(MCRC): Updated results, multivariate and subgroups analisys of the G.O.N.O. randomized phase III study (2007) (0)
Folfoxiri improves survival compared to folfiri as first-line treatment of metastatic colorectal cancer (MCRC): updated results of a randomized phase III study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) (2006) (0)
Optimal preoperative staging and early detection of lung metastases for patients affected by invasive intraductal papillary mucinous neoplasms )IPMNs) of the pancreas. (2012) (0)
652PEGFR AND AKT1 OVEREXPRESSION ARE MUTUALLY EXCLUSIVE AND ASSOCIATED WITH A POOR SURVIVAL IN RESECTED ADENOCARCINOMAS OF THE STOMACH AND GASTRO-ESOPHAGEAL JUNCTION. (2014) (0)
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). (2022) (0)
5-Fluorouracil exposure in adjuvant chemotherapy regimens is significantly related to disease free survival in colorectal cancer patients (2006) (0)
[ASCO 2006 Annual Meeting, Atlanta, June 2-6, 2006. Focus on gastrointestinal tumors]. (2006) (0)
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine, irinotecan, and oxaliplatin (XELOXIRI): Preliminary results of a pilot study by the G.O.N.O. Group (2007) (0)
Perioperative Morbidity Following Cytoreductive Surgery Combined with Intraperitoneal Chemohyperthermia in a Novel Italian Centre (2020) (0)
223Ra-chloride therapy: the first multidisciplinary and multicenter Italian study. (2017) (0)
Clinical and genetic characterization of dihydropyrimidine dehydrogenase (DPD) deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele (2011) (0)
L16Prognostic model for patients (pts) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (mFOLFIRINOX) (2015) (0)
Let-7 micro-RNA levels in KRAS mutated colorectal carcinomas impact on survival of patients treated with salvage cetuximab (2011) (0)
Reply (2004) (0)
Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study. (2016) (0)
A phase II pilot study of sequential chemo-immunotherapy with capecitabina+ interferon α2A (IFN) followed by interleukina-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC): on behalf of the Gruppo Oncologico Nord Ovest (G.O.N.O.) (2006) (0)
P-0262 Prospective Evaluation of Candidate Snps of Vegf/Vegfr Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line Folfiri Plus Bevacizumab (BV) (2012) (0)
Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics? (2012) (0)
Cytokinetic-based versus conventional chemotherapy in metastatic breast cancer: a randomized study. (1987) (0)
Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: A pooled analysis of GONO studies. (2016) (0)
A retrospective analysis of patients (pts) with non-small-cell lung cancer (NSCLC) with uncommon or complex epidermal growth factor receptor (EGFR) mutations treated with tyrosine kinase inhibitors (EGFR-TKIs): clinical features and outcome. (2017) (0)
The role of post-mastectomy radiotherapy (PMRT) and prognostic factors of locoregional recurrence (2017) (0)
immune in colorectal cancers with microsatellite instability by digital cancers(CRCs)leadtohighlevelsofmicrosatelliteinstability(MSI-h)causingconsid-erableendogenousimmuneanti-tumorresponse,counterbalancedbyimmuneinhibi-torysignals.WeevaluatedthemRNAimmune-profileofaseriesofMSI-hCRCstoidentifynewpot (2018) (0)
P-284Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: European subgroup (2015) (0)
Polymorphisms in the telomerase complex to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials. (2019) (0)
Genetic variants involved in bromodomain-containing protein 4 (BRD4) regulating pathway to predict outcomes in patients with metastatic colorectal cancer: Results from FIRE3 and MAVERICC trials. (2020) (0)
Genetic variations in semaphorin/neuropilin signaling to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab-based chemotherapy. (2017) (0)
Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study. (2016) (0)
Sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) (2007) (0)
S41G1-G2 Neuroendocrine Tumors (WD NET) in treatment with Capecitabine (Cp) plus somatostatin analog (SSA) (2016) (0)
Folfiri as third-line treatment in metastatic gastric cancer. (2012) (0)
This is a repository copy of Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B (2019) (0)
Chemotherapy and immunotherapy in metastatic colorectal cancer. (2009) (0)
Induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) + BV and surgery in locally advanced rectal carcinoma (LARC): The phase II TRUST trial. (2016) (0)
TRIBE study: are all three cytotoxic drugs crucial? - Authors' reply. (2015) (0)
705PPREMATURE MORTALITY IN PANCREATIC CANCER: ANALYSIS OF LOST LIFE-YEARS AND QUALITY-ADJUSTED LIFE-YEARS (QALYS) IN EUROPE. (2014) (0)
SOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy (2019) (0)
Surrogate markers for antiangiogenetic therapy: circulating endothelial cells and progenitors durino bevacizumab-based treatment in colorectal cancer (2008) (0)
EZH2 Expression in Colorectal (CRC) Cancer: Single Nucleotide Polymorphism (SNP) Characterization and Correlation With Clinico-Pathological and Molecular Parameters (2012) (0)
C01*The detection of AR-V7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients (2016) (0)
Chemotherapy Intensifi cation (2007) (0)
2372 Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer (2015) (0)
A18Whole-exome sequencing of HER-2 positive human breast cancers: potential molecular mechanisms of response to neoadjuvant chemotherapy plus trastuzumab (2015) (0)
Can tumor location predict effectiveness of bevacizumab conduc-ted in the ﬁ rst-line setting for metastatic colorectal cancer (2014) (0)
Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC). (2019) (0)
Acknowledgement to reviewers (2015) (0)
Impact OF PIK3CA Mutations and P95HER2 Expression on the Outcome of HER2-Positive Metastatic Breast Cancer Patients Treated With a Trastuzumab-Based Therapy (2012) (0)
Prognostic value of primary tumor resection in synchronous metastatic colorectal cancer (mCRC): Individual patient data (IPD) analysis of first-line randomized trials from the ARCAD database. (2016) (0)
Adjuvant gemcitabine-based chemoradiation compared to gemcitabine alone following radical surgical resection for pancreatic ductal adenocarcinoma (PDAC): a retrospective analysis (2010) (0)
Genetic Interaction Profile May Predict Bevacizumab (BV) Efficacy in Metastatic Breast Cancer (MBC) Patients (PTS): An Exploratory Retrospective Analysis (2012) (0)
An intention to treat (ITT) evaluation of docetaxel chemotherapy rechallenge in metastatic castration-resistant prostate cancer (mCRPC) (2011) (0)
Cigarettes smoking habit may induce a reduced efficacy of cetuximab-based treatment in advanced colorectal cancer patients (2008) (0)
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study (2020) (0)
Analysis of tumor response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or Gemcitabine + Nab-Paclitaxel (2018) (0)
7036 Phase II study with pharmacodynamic evaluation of docetaxelprednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC) (2009) (0)
Preoperative fluorouracil (FU)-based chemoradiation +/- weekly oxaliplatin in locally advanced rectal cancer. Pathologic response analysis of the star (Studio terapia adiuvante retto)-01 randomized phase III trial (2010) (0)
Abstract P1-08-31: Putative role of genetic variants of eNOS in survival and toxicity of patients given antiangiogenic therapy (2013) (0)
Chemioterapia, ormonoterapia e modificatori della risposta biologica (1999) (0)
Polymorphisms interaction to predict bevacizumab (BV) efficacy in metastatic breast cancer (MBC) patients: an exploratory retrospective analysis. (2013) (0)
FOLFIRNOX for advanced pancreatic cancer (aPDAC) according to schedule and dose modifications: Clinical feasibility and impact of supportive care. (2015) (0)
Integrating liquid biopsy with advanced imaging analysis to improve the prediction of response to immunotherapy in patients with NSCLC. (2019) (0)
First line treatment of metastatic colorectal cancer (MCRC) with the combination of capecitabine ( C ), irinotecan ( I ) and oxaliplatin ( O ) (XELOXIRI): a pilot study by the Gruppo Oncologico Nord Ovest (G.O.N.O.) (2007) (0)
The impact of Th17 cell pathway-related genetic variants in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy. (2018) (0)
AB046. P017. Identification of pathological ampullary adenocarcinomas subtypes and their prognosis using the immunohistochemical score of CDX2, CK7 and CK 20 (2018) (0)
Impact of polymorphisms within genes involved in regulating DNA methylation in metastatic colorectal cancer patients enrolled in three independent, randomized, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC, and FIRE-3. pathways on outcomes in (2019) (0)
Prevention of Capecitabine Toxicity Using a 5-FU Test Dose (2018) (0)
Trastuzumab Resistance in HER2 +ve Metastatic Breast Carcinoma Patients (2014) (0)
PCN34 EFFECT OF METASTASIS LOCALIZATION ON SYMPTOMS AND ASSISTANCE COSTS IN ADVANCED NSCLC PATIENTS. FURTHER EVIDENCE FROM THE HABIT STUDY (2006) (0)
Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3. (2019) (0)
Metronomic chemotherapy (MC) with oral uracil/tegafur (UFT), cyclophosphamide (CTX) and celecoxib in pretreated patients with advanced gastrointestinal cancers: a pilot clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations (2008) (0)
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study. (2022) (0)
Metastatic melanoma patients treated with Braf and Mek inhibitors: Patterns of progression. An Italian Melanoma Intergroup study. (2017) (0)
4029 POSTER Phase II clinical trial of metronomic cyclophosphamide (CTX) plus celecoxib (C) and dexamethasone (DEX) in advanced hormone refractory prostate cancer (HRPC): preliminary clinical and pharmacodynamic results (2007) (0)
Detection of BRAF and KRAS mutations in DNA released by tumors in peripheral blood by an advanced digital droplet PCR. (2013) (0)
Sequence E ffect o f I rinotecan a nd F luorouracil T reatment on P harmacokinetics a nd T oxicity i n C hemotherapy-Nai ve Metastatic C olorectal C ancer P atients (2001) (0)
State-of-the-art strategies in first line treatment of colorectal cancer (2009) (0)
1005 ORAL HER-3, IGF-1, NF K-B and EGFR Gene Copy Number in the Prediction of Clinical Outcome for Colorectal Cancer Patients Receiving Irinotecan-cetuximab (2011) (0)
Third-Line Folfiri in Metastatic Gastric Cancer Patients (2012) (0)
FIRST EXPERIENCE IN COLORECTAL SURGERY WITH THE NEW INTEGRATED TABLE MOTION FOR THE DA VINCI XI SURGICAL SYSTEM (2016) (0)
Results of the phase II TRUST trial of induction treatment with FOLFOXIRI + bevacizumab (BV) followed by chemo-radiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC). (2016) (0)
Relative dose intensity (RDI) of intravenous (IV) cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in patients with stage I-III breast cancer receiving pegfilgrastim support (2006) (0)
Genetic modulation of the LET-7 micro-RNA binding to KRAS 3’-untranslated region (3’-UTR) impacts on survival of metastatic colorectal cancer (MCRC) patients (pts) with unresponsive disease to salvage cetuximab-irinotecan (2009) (0)
Bevacizumab (BV) in combination with folfoxiri compared to BV plus folfiri as first-line treatment of metastatic colorectal cancer (MCRC): preliminary safety results of the tribe study bu the Gruppo Oncologico Nord-Ovest (GONO) (2010) (0)
Progressing G1-G2 neuroendocrine tumors (WD NET) in treatment with capecitabine (Cp) plus somatostatin analog (SSA): a single center experience (2016) (0)
R34Metastatic well or moderately differentiated Neuroendocrine tumors (WDNET) treated with sequences of different Somatostatin Analogs (SSA) - Lanreotide LAR (La), Octreotide LAR (Oc): a single center experience (2015) (0)
Is a new line with cetuximab re treatment feasible and active in metastatic colorectal cancer (CRC) patients (2009) (0)
Cx. Incorporation of ctDNA analysis into routine follow-up for early detection of relapse may allow earlier initiation of alternate treatment modalities. Legal entity responsible for the study: The National Committee on Health Research (2019) (0)
D3-06: Correlation of cytidine deaminase and DNA repair genes polymorphisms with response and survival in gemcitabine/cisplatin treated advanced non-small-cell lung cancer patients (2007) (0)
Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver-limited metastatic colorectal cancer (mCRC). (2018) (0)
Correlation of immunological effects of anti-VEGF therapy with progression-free survival of advanced colorectal cancer patients. (2009) (0)
Characterization of mismatch repair deficiency in biliary tract cancer. (2019) (0)
Polycomb gene expression and single-nucleotide-polymorphisms (SNPS) in triple negative breast cancer (TNBC) patients. (2012) (0)
Sorafenib plus daily low dose temozolomide for relapsed glioblastoma: A phase II study. (2011) (0)
The immune-profile of mismatch repair deficient (dMMR) colorectal cancers (CRCs) differs according to primary tumor sidedness. (2018) (0)
Immunological effects of the anti-vegf therapy: an additional mechanism of action in colorectal cancer patients? (2008) (0)
PD-0009 Primary Tumor Location is a Major Independent Prognostic Factor for Mcrc Patients (2012) (0)
A randomized clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL (Docetaxel in Second-Line Treatment of Advanced Lung Cancer) (2004) (0)
EP-1282: Clinical and pathological prognostic factors in locally advanced rectal cancer (larc) (2017) (0)
Efficacy and safety of everolimus and exemestane for metastatic breast cancer patients: a real-life experience of three Oncology Departments. (2017) (0)
Small Cell Lung Cancer Patients − Advanced Non Treated − Response and Survival in Gemcitabine / Cisplatin Polymorphisms with XPD , and CDA , ERCC 1 Correlation of (2008) (0)
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib (2019) (0)
Cisplatin plus gemcitabine as adjuvant chemotherapy for resected non-small cell lung cancer (NSCLC): a phase II tolerability study (2008) (0)
A phase II activity and safety study of oral doxifluridine (5′-dFUR) in elderly patients with advanced non small cell lung cancer (NSCLC) (1994) (0)
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients (2019) (0)
Evaluation of safety and activity of everolimus plus exemestane in metastatic breast cancer: A single institution experience. (2016) (0)
PD-0009PROSPECTIVE ANALYSIS OF THE EARLY MODULATION OF PLASMA AMPHIREGULIN DURING TREATMENT WITH CETUXIMAB AND IRINOTECAN IN METASTATIC COLORECTAL CANCER PATIENTS (2013) (0)
Therapeutic strategies in unresectable disease: doublet therapy, triplet therapy and targets (2011) (0)
Development and validation of a prognostic score for overall survival integrating baseline metabolically active tumor volume measured by 18F-FDG PET/CT and clinical factors for metastatic colorectal cancer patients. (2019) (0)
E07DPYD c.1905 + 1G > A and c.2846A > T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer (2015) (0)
Phase II clinical trial with pharmacokinetics (PK) and pharmacodynamics (PD) evaluation of metronomic oral vinorelbine (V) and dexamethasone (D) in patients with advanced castration resistant prostate cancer (CRPC): final clinical results (2011) (0)
3051 POSTER Phase II trial of sequential chemotherapy with capecitabine and irinotecan followed by capecitabine and oxaliplatin in elderly vulnerable patients (pts) with metastatic colorectal cancer (MCRC) (2007) (0)
Familial cancer and genetic syndromes (2012) (0)
[Postoperative chemotherapy in rectal carcinoma]. (2001) (0)
P-188 Safety and efficacy of first-line gemcitabine plus nab-paclitaxel for elderly metastatic pancreatic cancer patients (2020) (0)
Report Congressuali: G.I. Cancer, 43○ ASCO Annual Meeting (2007) (0)
Case-report: folfoxiri plus bevacizumab in "poor-risk" liver-only metastatic colorectal cancer: case report and state-of-the-art. (2013) (0)
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer (2017) (0)
TRIBE2 results and toxicity - Authors' reply. (2020) (0)
Report Congressuali: ASCO 2006 Gastrointestinal Cancer Symposium (2006) (0)
6602 Prognostic relevance of lymph node metastases and adjuvant treatment for patients with invasive intraductal papillary mucinous (IPMNs) of the pancreas (2009) (0)
Insulin-like growth factor-1 (IGF-1) correlates with clinical outcome in metastatic colorectal patients treated with irinotecan/cetuximab combination (2008) (0)
First line chemotherapy with sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer (NSCLC) patients: a multicenter phase II study (2007) (0)
Phase II trial nof non-pegylated liposomal doxorubicin (MYOCET ® ) associated with weekly docetaxel in metastatic breast cancer (2007) (0)
Selective induction of PD-L1 expression in plasma-derived exosomes by gem-nab-paclitaxel vs. folfirinox in pancreas cancer. (2018) (0)
A41Evaluation of safety and activity of everolimus plus exemestane in metastatic breast cancer: a single institution experience (2015) (0)
Impact of IVS14+1G>A and 2846A>T DPYD polymorphisms on toxicity outcome of patients treated with fluoropyrimidine-containing regimens. (2013) (0)
Associations of incidence of common adverse events (AEs) and survival outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line chemotherapy: Findings from 9,812 pts in the ARCAD database. (2018) (0)
1148POCTREOTIDE LAR SUITABLE TREATMENT FOR G1-G2 THORACIC NEUROENDOCRINE TUMORS (T-NET): SINGLE CENTER EXPERIENCE. (2014) (0)
Metronomic oral vinorelbine (V) and dexamethasone (D) in patients with advanced castration resistant prostate cancer (CRPC): a phase II clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations (2009) (0)
2249 Comparison of Everolimus (EV) plus somatostatin analog (SSA) administered before or after chemotherapy (CT) or PRRT in advanced G1-G2 Neuroendocrine Tumor (NET) progressed after SSA: analysis of different sequences in single center experience (2015) (0)
Selective induction of PD-L1 expression in plasma-derived exosomes by gemcitabine-nab-paclitaxel vs. FOLFIRINOX in pancreas cancer. (2018) (0)
Abstract P5-17-06: The deficient eNOS c.894G>T genotype is not associated with increased severity of hypertension and proteinuria in breast cancer patients receiving bevacizumab (2012) (0)
303PCARDIAC SAFETY ASSESSMENT OF ADJUVANT NONPEGYLATED LIPOSOMAL DOXORUBICIN (NPLD) PLUS CYCLOPHOSPHAMIDE (C) FOLLOWED BY PACLITAXEL (P) IN ELDERLY BREAST CANCER (EBC) WOMEN. (2014) (0)
Prognosis and chemotherapy sensitivity of metastatic biliary cancers according to primary tumor site (2010) (0)
Adjuvant chemotherapy with fluorouracil and levamisole alone or in combination with 6-S-leucovorin for the treatment of colon cancer: randomized multicenter trial of the Italian Intergroup (INTACC) (2003) (0)
Combination of trastuzumab, oxaliplatin and docetaxel as first line treatment in HER2-positive advanced breast cancer patients: preliminary results of a phase II trial (HOT Trial) (2009) (0)
Use of early modifications of circulating endothelial cell (CEC) apoptotic profile as surrogate biomarkers in bevacizumab-based treatment for advanced colorectal cancer patients (2010) (0)
Genetic variation in TET3 and survival in metastatic colorectal cancer (mCRC) from FIRE-3, TRIBE, and MAVERICC clinical trials. (2018) (0)
A Pilot Study of a Day One and Eight Every Three Weeks Administration of Docetaxel in Metastatic Cancer Patients (2007) (0)
A pharmacokinetic-based test to predict the risk of life-threatening 5-fluorouracil toxicities in cancer patients. (2004) (0)
R37Predictive factors of efficacy of Somatostatine Analogs (SSA) in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) (2015) (0)
Biomarker validation study: Genes involved in ubiquitin proteasome system (UPS) dependent EGFR-degradation for prediction of efficacy in metastatic colorectal cancer patients treated with cetuximab. (2014) (0)
Circulating endothelial cells (CECs) kinetic correlates with clinical response in metastatic colorectal cancer patients during first-line bevacizumab-based treatment (2009) (0)
Abstract 2614: Macrophage erythroblast attacher (MAEA) polymorphisms are associated with clinical outcome in TRIBE study mCRC patients treated with 5-fluorouracil/bevacizumab-based therapy (2018) (0)
Association of PD-L1 mRNA levels in plasma-derived exosomes with response to nivolumab and pembrolizumab in melanoma and NSCLC. (2018) (0)
Clinical presentation in BRCA1/2 mutation carriers: a single-institution experience. (2012) (0)
Metronomic chemotherapy (MC) with irinotecan (CPT-11) in patients with diagnosis of metastatic colorectal cancer (MCRC): clinical, pharmacodynamic (PD) and pharmacokinetic (PK) evaluation. Final report (2007) (0)
Reply to the Letter to the Editor on ‘Cost-opportunity analysis in clinical oncology: from the “wild far-west” to a correct integration of the disciplines, avoiding the “war of the worlds”’, by D. Tassinari et al. (Ann Oncol 2006; 17: 876) (2006) (0)
Focus sui tumori gastrointestinali (2006) (0)
First-line folfoxiri followed by R0 surgical resection of metastases in unresectable metastatic colorectal cancer (MCRC) patients (pts) (2007) (0)
Front & Back Matter (2012) (0)
The role of transvaginal ultrasound in early diagnosis of tamoxifen-related endometrial cancer: An Italian experience (2007) (0)
2253 Interferon-based adjuvant chemoradiation in patients with resected pancreatic adenocarcinoma: Long-term outcomes (2015) (0)
Abstract PS10-24: Infusion related reactions in the phase 3 SOPHIA trial of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with pretreated HER2+ metastatic breast cancer (2021) (0)
Docetaxel-prednisone (DP) plus metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC): phase II trial with pharmacodynamic evaluation (2009) (0)
Evaluation of cost-effectiveness of early KRAS testing in high-risk recurrence colorectal cancer patients in Italy. (2012) (0)
PO-0665: The role of post-mastectomy radiotherapy (PMRT) and prognostic factors of locoregional recurrence (2017) (0)
Corrections to "Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?" (2017) (0)
Preliminary experience with Xenotransplantation of pancreatic cancer samples in zebrafish embryos: towards personalized medicine (2019) (0)
IRS1 and IRS2 polymorphisms and outcome in mCRC patients enrolled in the FIRE-3 trial. (2016) (0)
ResearchMagnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer : meta-analysis of randomized clinical trials (2015) (0)
E30KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: a case-control study (2015) (0)
Atypical RAS Mutations in Metastatic Colorectal Cancer (2019) (0)
PCN49 INDIRECT COMPARISON OF HRQOL DATA FOR PATIENTS WITH TREATMENT-REFRACTORY METASTATIC COLORECTAL CANCER TREATED WITH TRIFLURIDINE & TIPIRACIL (PRECONNECT TRIAL) COMPARED WITH BSC & REGORAFENIB (CORRECT TRIAL) (2019) (0)
1145PEFFICACY OF SOMATOSTATIN ANALOGS (SSA) IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NET) ACCORDING TO KI67 INDEX: A SINGLE CENTRE EXPERIENCE. (2014) (0)
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients? (2019) (0)
2255 Safety and effectiveness of the combination of single chemotherapeutic agent (gemcitabine) with radiotherapy in radically resected pancreatic adenocarcinoma (2015) (0)
F41Prognostic role of pregnancy in breast cancer patients. a single institution experience (2016) (0)
Polymorphisms of pluripotency transcription factors for predicting cetuximab efficacy in metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials. (2021) (0)
S17Antiemetic prophylaxis (AP) in our clinical practice: are we doing it right? (2016) (0)
517PFOLFOXIRI PLUS BEVACIZUMAB (BEV) AS FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS). (2014) (0)
[Metastatic colorectal cancer: adjournments from ESMO 2006]. (2006) (0)
Docetaxel as second-line treatment in metastatic gastric cancer. (2012) (0)
Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes to predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevacizumab in TRIBE trial. (2018) (0)
Retrospective analysis of second-line chemotherapy in biliary tract cancer (2011) (0)
6080 Reintroduction of FOLFOXIRI treatment in metastatic colorectal cancer patients progressed after first-line FOLFOXIRI (2009) (0)
Development of a new clinical nomogram including velocity rate of disease progression to predict outcome in metastatic colorectal cancer patients treated with bevacizumab beyond progression: A subanalysis from tribe trial. (2018) (0)
Impact of dose reduction on survival in patients starting sunitinib (SU) or pazopanib (PA) as first-line for metastatic renal cell carcinoma (mRCC). (2016) (0)
AN EZH2 POLYMORPHISMS IS ASSOCIATED WITH CLINICAL OUTCOME IN METASTATIC COLORECTAL CANCER PATIENTS. (2012) (0)
Tandem repeat variation in HIC1 gene predicts outcome for oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer (2016) (0)
Quantitative evidence for early metastatic seeding in colorectal cancer (2019) (0)
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. (2012) (0)
Genetic variants of kinases suppressors of ras in KRAS-BRAF wild-type metastatic colorectal cancer patients treated with cetuximab and irinotecan. (2012) (0)
FOLFIRINOX in pancreatic cancer: from state of the art treatments to promising translational studies for personalized therapy (2020) (0)
Survival outcomes among older adults (OA) receiving second-line therapy for metastatic CRC (mCRC): 5,289 patients (pts) from the ARCAD Clinical Trials Program. (2020) (0)
Estrogenic Recruitment Followed by Chemotherapy in Breast Cancer: Experimental and Clinical Results (1987) (0)
First-line chemotherapy with planned sequential administration of gemcitabine (G) followed by docetaxel (D) in elderly advanced non-small-cell lung cancer (NSCLC) patients: A multicenter phase II study (2008) (0)
1247PPatterns of progression in metastatic melanoma patients treated with Braf and Mek inhibitors: an Italian Melanoma Intergroup (IMI) study (2017) (0)
101P Accuracy of detecting PIK3CA mutations on circulating tumour (ct) DNA as compared to tumour tissue (TT) in breast cancer (BC) patients (pts): Results from a systematic review and meta-analysis (2020) (0)
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer (2022) (0)
EZH 2 polymorphism and benefit from bevacizumab in colorectal cancer : another piece to the puzzle (2012) (0)
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer (2012) (0)
610TiPA randomized Phase 2 study comparing different dosing approaches of induction treatment (first cycle) of regorafenib in metastatic colorectal cancer (mCRC) patients (2017) (0)
CARAMEL study: Clinical prognostic biomarkers for ipilimumab-related outcome in metastatic melanoma patients (2016) (0)
Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials (2023) (0)
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer (2020) (0)
Erlotinib (E) treatment after failure of gefitinib (G) in advanced non-small-cell lung cancer (NSCLC) patients previously responding to EGFR tyrosine Kinase inhibitors (TKI) (2008) (0)
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies. (2019) (0)
2143 Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study (2015) (0)
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials (2018) (0)
An interview with Alfredo Falcone and Lisa Salvatore: RECOURSE and trifluridine/tipiracil in metastatic colorectal cancer. (2016) (0)
THE IMMUNOHISTOCHEMICAL SCORE OF CDX2, CK7 AND CK 20 CAN IDENTIFY PATHOLOGICAL SUBTYPES OF AMPULLARY ADENOCARCINOMAS AND THEIR PROGNOSIS (2019) (0)
Genetic variants within the glucocorticoids related genes to predict outcome in patients with metastatic colorectal cancer (mCRC). (2018) (0)
Second-line (SL) chemotherapy containing oxaliplatin (OXA) in metastatic pancreatic cancer (PC): Whom should we trust? (2017) (0)
6051 Balancing pros and cons of the addition of Bevacizumab (BEVA) to first-line chemotherapy (CT) for advanced/metastatic colorectal cancer (MCRC): Meta-analysis of randomized clinical trials exploring absolute benefits (2009) (0)
F34Retrospective observational analysis of bevacizumab (BV) plus paclitaxel (TXL) as first line treatment in metastatic HER2 negative breast cancer (BC): are BV long responders a different subgroup? (2016) (0)
Phase II study of cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (2008) (0)
Strategie di prevenzione e cura in oncologia: differenze di genere (2014) (0)
Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer. (2019) (0)
F35Young women with metastatic breast cancer (mbc): a restrospective single institution analysis of clinical-pathological characteristics and outcomes (2016) (0)
L01*Age subgroup analysis of efficacy and safety data from two phase 3 studies of second-line ramucirumab (RAM) versus placebo (PL) in patients (pts) with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINBOW and REGARD) (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Alfredo Falcone?

Alfredo Falcone is affiliated with the following schools:

Alfredo Falcone's Academic­Influence.com Rankings

Alfredo Falcone's Degrees

Similar Degrees You Can Earn

Why Is Alfredo Falcone Influential?

Alfredo Falcone's Published Works

Published Works

What Schools Are Affiliated With Alfredo Falcone?

Alfredo Falcone's AcademicInfluence.com Rankings